Background of the Invention Currently, non-surgical cancer treatment regimes involve administering one or more highly toxic chemotherapeutics or hormonal therapies to the patient after the cancer has progressed to a point where the therapeutic benefits of chemotherapy/hormonal outweigh its serious side effects. As a consequence of these side effects, standard chemotherapeutics are typically used only for short periods of time, often alternating chemotherapy with periods off treatment, so as not to overwhelm the patient with drug side effects. Accordingly, given the risk-benefit trade-off, side effects typically preclude starting chemotherapy when patients exhibit precancerous lesions, or continuing chemotherapy or hormonal therapy on a chronic basis after cancer has been eliminated in an attempt to prevent its re-occurrence.

Cancer and precancer research is replete with publications that describe various biochemical molecules that are over-expressed in neoplastic tissue, leading several groups to research whether specific over-expressed molecules are responsible for the disease, and whether, if such over-expression were inhibited, neoplasia could be alleviated. One such biochemical molecule that has been extensively studied as a therapeutic target for neoplasia treatment is the prostaglandins, which are naturally occurring C-20 unsaturated fatty acids. By way of example, in familial adenomatous

polyposis ("FAP"), Waddell et al. hypothesized that since prostaglandins were over- expressed in such polyps, non-steroidal anti-inflammatory drugs ("NSAIDs") should alleviate the condition because NSAIDs inhibited prostaglandin synthesis. Thus, he administered the NSAID sulindac (an inhibitor of PGE2) to several FAP patients.

Waddell et al. discovered that polyps regressed and did not recur upon therapeutic treatment with an NSAID. PGE2 inhibition results from the inhibition of cyclooxygenase (COX) by NSAIDS.

While patients treated with NSAIDS typically exhibit far fewer side effects than with conventional chemotherapeutics or hormonals, the use of high doses of most common NSAIDs can produce severe side effects, including life-threatening ulcers that limit their therapeutic potential. One reason proposed for the severe side effects associated with traditional NSAms is their non-selective inhibition of both of the cyclooxygenase enzymes (COX), commonly known as COX-1 and COX-2. COX-1 is constitutively expressed and mediates a number of physiological functions, such as kidney and gastrointestinal function. COX-2 expression, contrastingly, is stimulated by a number of inflammatory cytokines, growth factors, oncogenes, lipopolysaccharides, and tumor promoters. While conventional NSAIDs block both forms of the enzyme, a new class of NSAID, selective cyclooxygenase-2 inhibitors, provide a viable target of inhibition that more effectively reduces inflammation and produces fewer and less drastic side effects.

COX-2 plays a key role in tumorigenesis through stimulating epithelial cell proliferation, inhibiting apoptosis, stimulating angiogenesis, enhancing cell invasiveness, mediating immune suppression, and by increasing the production of mutagens. Results of several studies using mouse models of colon cancer and the results of clinical trials have shown COX-2 to be a useful target for the prevention and treatment of colon cancer (Fernandex et al. , (2002) In Vivo 16 (6): 501-509). Studies with several other epithelial cancers involving different organ sites, e. g. , breast, prostate, bladder, lung, and pancreas, suggest that COX-2 plays an important role in the pathogenesis of these cancers (e. g. for its role in breast cancer see Singh et al. , (2002) J. Surg. Res. 108 (1) : 173-179; for its role in fibroblasts and endothelial cells see Sonoshita et al. , (2002) Cancer Res. 62 (23): 6846- 6849; for its role in gastric cells see Li et al., (2002) 21 (6): 625-629).

Summary of the Invention Among the several aspects of the invention is provided a method and a composition for the treatment of neoplasia in a subject. The composition comprises a cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof and a carbonic anhydrase inhibitor or pharmaceutically acceptable salt or prodrug thereof. In another aspect, the method comprises administering to the subject a cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof in combination with a carbonic anhydrase inhibitor or pharmaceutically acceptable salt or prodrug thereof.

In one embodiment, the cyclooxygenase-2 selective inhibitor is a member of the chromene class of compounds. For example, the chromene compound or pharmaceutically acceptable salt or prodrug thereof may be a compound of the formula : wherein: n is an integer which is 0, 1, 2,3 or 4; G is O, S or NRa ; Ra is alkyl ; Rl is selected from the group consisting of H and aryl; R2 is selected from the group consisting of carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl ; R3 is selected from the group consisting of haloalkyl, alkyl, aralkyl, cycloalkyl and aryl optionally substituted with one or more radicals selected from alkylthio, nitro and alkylsulfonyl ; and each R4 is independently selected from the group consisting of H, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl,

heteroaralkylaminosulfonyl, heterocyclosulfonyl, alkylsulfonyl, hydroxyarylcarbonyl, nitroaryl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, and alkylcarbonyl; or wherein R4 together with the carbon atoms to which it is attached and the remainder of ring E forms a naphthyl radical.

In another embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof comprises a compound of the formula: wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings; Ri is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein Rl is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; R2 is selected from the group consisting of methyl or amino; and R3 is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N- arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino,

N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N- alkyl-N-arylaminosulfonyl.

In yet another embodiment, the carbonic anhydrase inhibitor is dorzolamide. In another embodiment, the carbonic anhydrase inhibitor is acetazolamide. In still another embodiment, the carbonic anhydrase inhibitor is dichlorophenamide. In yet a further embodiment, the carbonic anhydrase inhibitor is brinzolamide. In another embodiment, the carbonic anhydrase inhibitor is methazolamide.

Other aspects of the invention are described in more detail below.

Abbreviations and Definitions The term"acyl"is a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals.

Examples of such lower alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl.

The tenn"alkenyl"is a linear or branched radical having at least one carbon- carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are"lower alkenyl"radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl.

The terms"alkenyl"and"lower alkenyl"also are radicals having"cis"and"trans" orientations, or alternatively, "E"and"Z"orientations. The term"cycloalkyl"is a saturated carbocyclic radical having three to twelve carbon atoms. More preferred cycloalkyl radicals are"lower cycloalkyl"radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The terms"alkoxy"and"alkyloxy"are linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are"lower alkoxy"radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.

The term"alkoxyalkyl"is an alkyl radical having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.

The"alkoxy"radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are"lower haloalkoxy"radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

The term"alkoxycarbonyl"means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower alkoxycarbonyl"radicals with alkyl porions having 1 to 6 carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.

Where used, either alone or within other terms such as"haloalkyl", "alkylsulfonyl","alkoxyalkyl"and"hydroxyalkyl", the term"alkyl"is a linear, cyclic or branched radical having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are"lower alkyl"radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like.

The term"alkylamino"is an amino group that has been substituted with one or two alkyl radicals. Preferred is"lower N-alkylamino"radicals having alkyl portions having 1 to 6 carbon atoms. Suitable lower alkylamino may be mono or dialkylamino such as N-methylamino, N-ethylamino, N, N-dimethylamino, N, N-diethylamino or the like.

The term"alkylaminoalkyl"is a radical having one or more alkyl radicals attached to an aminoalkyl radical.

The term"alkylaminocarbonyl"is an aminocarbonyl group that has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are"N- alkylaminocarbonyl""N, N-dialkylaminocarbonyl"radicals. More preferred are"lower N-alkylaminocarbonyl""lower N, N-dialkylaminocarbonyl"radicals with lower alkyl portions as defined above.

The terms"alkylcarbonyl","arylcarbonyl"and"aralkylcarbonyl"inclu de radicals having alkyl, aryl and aralkyl radicals, as defined above, attached to a carbonyl radical.

Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl.

The term"alkylthio"is a radical containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are"lower alkylthio"radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio.

The term"alkylthioalkyl"is a radical containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms.

More preferred alkylthioalkyl radicals are"lower alkylthioalkyl"radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl.

The term"alkylsulfinyl"is a radical containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent-S (=O)- radical. More preferred alkylsulfinyl radicals are"lower alkylsulfinyl"radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl.

The term"alkynyl"is a linear or branched radical having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are"lower alkynyl"radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.

The term"aminoalkyl"is an alkyl radical substituted with one or more amino radicals. More preferred are"lower aminoalkyl"radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like.

The term"aminocarbonyl"is an amide group of the formula-C (=0) NH2.

The term"aralkoxy"is an aralkyl radical attached through an oxygen atom to other radicals.

The term"aralkoxyalkyl"is an aralkoxy radical attached through an oxygen atom to an alkyl radical.

The term"aralkyl"is an aryl-substituted alkyl radical such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable.

The term"aralkylamino"is an aralkyl radical attached through an amino nitrogen atom to other radicals. The terms"N-arylaminoalkyl"and"N-aryl-N-alkyl-aminoalkyl" are amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical.

Examples of such radicals include N-phenylaminomethyl and N-phenyl-N- methylaminomethyl.

The term"aralkylthio"is an aralkyl radical attached to a sulfur atom.

The term"aralkylthioalkyl"is an aralkylthio radical attached through a sulfur atom to an alkyl radical.

The term"aroyl"is an aryl radical with a carbonyl radical as defined above.

Examples of aroyl include benzoyl, naphthoyl, and the like and the aryl in said aroyl may be additionally substituted.

The term"aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term"aryl"is an aromatic radical such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl.

The term"arylamino"is an amino group, which has been substituted with one or two aryl radicals, such as N-phenylamino. The"arylamino"radicals may be further substituted on the aryl ring portion of the radical.

The term"aryloxyalkyl"is a radical having an aryl radical attached to an alkyl radical through a divalent oxygen atom.

The term"arylthioalkyl"is a radical having an aryl radical attached to an alkyl radical through a divalent sulfur atom.

The term"carbonic anhydrase"as used herein refers to any isomer of the metalloprotein enzyme that catalyzes the interconversion Of C02 and H2CO3 (C02 + 02 HC02 + H).

The term"carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", is- (C=O)-.

The terms"carboxy"or"carboxyl", whether used alone or with other terms, such as"carboxyalkyl", is-C02H.

The term"carboxyalkyl"is an alkyl radical substituted with a carboxy radical.

More preferred are"lower carboxyalkyl"which are lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl.

The term"cycloalkenyl"is a partially unsaturated carbocyclic radical having three to twelve carbon atoms. More preferred cycloalkenyl radicals are"lower cycloalkenyl"radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl.

The term"cyclooxygenase-2 selective inhibitor"is a compound able to inhibit cyclooxygenase-2 without significant inhibition of cyclooxygenase-l. Preferably, it includes compounds that have a cyclooxygenase-2 IC50 of less than about 0.2 micro molar, and also have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1 IC50 of greater than about 1 micro molar, and more preferably of greater than 10 micro molar. Inhibitors of the cyclooxygenase pathway in the metabolism of arachidonic acid used in the present method may inhibit enzyme activity through a variety of mechanisms. By the way of example, and without limitation, the inhibitors used in the methods described herein may block the enzyme activity directly by acting as a substrate for the enzyme.

The term"halo"means halogens such as fluorine, chlorine, bromine or iodine.

The term"haloalkyl"is a radical wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical.

Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a

combination of different halo radicals."Lower haloalkyl"are radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

The term"heteroaryl"is an unsaturated heterocyclyl radical. Examples of unsaturated heterocyclyl radicals, also termed"heteroaryl"radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e. g., 4H-1, 2,4-triazolyl, lu-1, 2,3-triazolyl, 2H-1, 2,3-triazolyl, etc. ) tetrazolyl (e. g. 1H-tetrazolyl, 2H-tetrazolyl, etc. ), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e. g. , tetrazolo [1, 5-b] pyridazinyl, etc. ), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3-to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e. g. , 1,2, 4-oxadiazolyl, 1,3, 4-oxadiazolyl, 1,2, 5-oxadiazolyl, etc. ) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e. g. benzoxazolyl, benzoxadiazolyl, etc. ) ; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e. g. , 1,2, 4- thiadiazolyl, 1,3, 4-thiadiazolyl, 1,2, 5- thiadiazolyl, etc. ) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e. g., benzothiazolyl, benzothiadiazolyl, etc. ) and the like. The term also embraces radicals where heterocyclyl radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said"heterocyclyl group"may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino.

The term"heterocyclyl"is a saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radical, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms (e. g.

pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc. ) ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e. g. morpholinyl, etc. ) ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e. g. , thiazolidinyl, etc. ). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.

The term"heterocyclylalkyl"is a saturated and partially unsaturated heterocyclyl- substituted alkyl radical, such as pyrrolidinyhnethyl, and heteroaryl-substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienyhnethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy.

The term"hydrido"is a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical.

The term"hydroxyalkyl"is a linear or branched alkyl radical having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are"lower hydroxyalkyl"radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl.

The term"inhibition"as used herein means to decrease the severity of neoplasia or a neoplasia disorder as compared to that which would occur in the absence of the administration of a compound identified herein as either a COX-2 selective inhibitor or carbonic anhydrase inhibitor.

The term"inhibitor"when used herein unless otherwise indicated refers to an enzyme inhibitor such as an inhibitor of carbonic anhydrase or cyclooxygenase. Enzyme inhibitors are agents and/or compounds that stop, prevent, or reduce the rate of an enzymatic reaction via any mechanism including, but not limited to, competitive inhibition, noncompetitive inhibition, and uncompetitive inhibition.

The term"pharmaceutically acceptable"is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product ; that is the "pharmaceutically acceptable"material is relatively safe and/or non-toxic, though not necessarily providing a separable therapeutic benefit by itself. Pharmaceutically acceptable cations include metallic ions and organic ions. More preferred metallic ions

include, but are not limited to appropriate alkali metal salts, alkaline earth metal salts and other physiologically acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

The term"prevention"includes either preventing the onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of neoplasia in individuals at risk. Also encompassed by this definition is the prevention of initiation for malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing the neoplasia.

The term"prodrug"refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject. For example, a class of prodrugs of COX-2 inhibitors is described in US Patent No. 5,932, 598, herein incorporated by reference.

The term"subject"for purposes of treatment includes any human or animal subject who is susceptible to an adverese impact resulting from a decrease in blood flow to the central nervous system. The subject can be a domestic livestock species, a laboratory animal species, a zoo animal or a companion animal. In one embodiment, the subject is a mammal, In another embodiment, the mammal is a human being.

The term"sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, is divalent radicals-SO2-."Alkylsulfonyl"are alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are"lower alkylsulfonyl"radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl.

The"alkylsulfonyl"radicals may be further substituted with one or more halo atoms,

such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl","aminosulfonyl"and"sulfonamidyl"are NHZOZS-.

The phrase"therapeutically-effective"is intended to qualify the amount of each agent (i. e. the amount of cyclooxygenase-2 selective inhibitor and the amount of carbonic anhydrase inhibitor) which will achieve the goal of improvement in disorder severity and the frequency of incidence over no treatment or treatment of each agent by itself.

The term"treatment"includes partial or total inhibition of the neoplasia growth, spreading or metastasis, as well as partial or total destruction of the neoplasia cells.

Treatment also includes prevention of a neoplasia or related disorder.

Description of the Preferred Embodiments The present invention provides a combination therapy comprising the administration to a subject of a therapeutically effective amount of a COX-2 selective inhibitor in combination with a therapeutically effective amount of a second compound that is a carbonic anhydrase inhibitor. The combination therapy may be employed to treat or prevent neoplasia or a neoplasia related disorder. When administered as part of a combination therapy, the COX-2 selective inhibitor together with the carbonic anhydrase inhibitor provide enhanced treatment options as compared to administration of either the carbonic anhydrase inhibitor or the COX-2 selective inhibitor alone.

Cyclooxygefzase-2 Selective Inlzibitors A number of suitable cyclooxygenase-2 selective inhibitors or pharmaceutically acceptable salts or prodrugs may be employed in the composition of the current invention. In one embodiment, the cyclooxygenase-2 selective inhibitor can be, for example, the cyclooxygenase-2 selective inhibitor meloxicam, Formula B-1 (CAS registry number 71125-38-7) or pharmaceutically acceptable salt or prodrug thereof.

In yet another embodiment, the cyclooxygenase-2 selective inhibitor is the cyclooxygenase-2 selective inhibitor, 6-[[5-(4-chlorobenzoyl)-1, 4-dimethyl-lH-pyrrol-2- yl] methyl] -3 (2H)-pyridazinone, Formula B-2 (CAS registry number 179382-91-3) or pharmaceutically acceptable salt or prodrug thereof.

In yet another embodiment the cyclooxygenase-2 selective inhibitor is a chromene compound that is a substituted benzopyran or a substituted benzopyran analog, and even more typically, selected from the group consisting of substituted benzothiopyrans, dihydroquinolines, dihydronaphthalenes or a compound having Formula I shown below and possessing, by way of example and not limitation, the structures disclosed in Table lx.

Furthermore, benzopyran cyclooxygenase-2 selective inhibitors useful in the practice of the present methods are described in U. S. Patent No. 6,034, 256 and 6,077, 850 herein incorporated by reference in their entirety.

In one embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof is a chromene compound represented by Formula I wherein n is an integer which is 0,1, 2,3 or 4; wherein G is O, S or NRa; wherein Ra is alkyl ; wherein R1 is selected from the group consisting of H and aryl; wherein R2 is selected from the group consisting of carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl ;

wherein R3 is selected from the group consisting of haloalkyl, alkyl, aralkyl, cycloalkyl and aryl optionally substituted with one or more radicals selected from alkylthio, nitro and alkylsulfonyl ; and wherein each R4 is independently selected from the group consisting of H, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, heteroaralkylaminosulfonyl, heterocyclosulfonyl, alkylsulfonyl, hydroxyarylcarbonyl, nitroaryl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, and alkylcarbonyl; or wherein R4 together with the carbon atoms to which it is attached and the remainder of ring E forms a naphthyl radical.

The cyclooxygenase-2 selective inhibitor may also be a compound of Formula (I) or pharmaceutically acceptable salt or prodrug thereof wherein: n is an integer which is 0, 1, 2,3 or 4; G is 0, S or NRa ; Ru ils H; Ra is alkyl ; R2 is selected from the group consisting of carboxyl, aminocarbonyl, alkylsulfonylaminocarbonyl and alkoxycarbonyl; R3 is selected from the group consisting of haloalkyl, alkyl, aralkyl, cycloalkyl and aryl, wherein haloalkyl, alkyl, aralkyl, cycloalkyl, and aryl each is independently optionally substituted with one or more radicals selected from the group consisting of alkylthio, nitro and alkylsulfonyl ; and each R4 is independently selected from the group consisting of hydrido, halo, alkyl, aralkyl, alkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, haloalkyl, haloalkoxy, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, nitro, amino, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, heteroaralkylaminosulfonyl, heterocyclosulfonyl, alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aralkylcarbonyl, heteroarylcarbonyl, arylcarbonyl,

aminocarbonyl, and alkylcarbonyl ; or wherein R4 together with ring E forms a naphthyl radical.

In a further embodiment, the cyclooxygenase-2 selective inhibitor may also be a compound of Formula (I), or pharmaceutically acceptable salt or prodrug thereof; wherein: n is an integer which is 0,1, 2,3 or 4; G is oxygen or sulfur; R'is H ; R is carboxyl, lower alkyl, lower aralkyl or lower alkoxycarbonyl ; R3 is lower haloalkyl, lower cycloalkyl or phenyl; and each R4 is H, halo, lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, lower alkylamino, nitro, amino, aminosulfonyl, lower alkylaminosulfonyl, 5-membered heteroarylalkylaminosulfonyl, 6-membered heteroarylalkylaminosulfonyl, lower aralkylaminosulfonyl, 5-membered nitrogen-containing heterocyclosulfonyl, 6- membered-nitrogen containing heterocyclosulfonyl, lower alkylsulfonyl, optionally substituted phenyl, lower aralkylcarbonyl, or lower alkylcarbonyl; or wherein R4 together with the carbon atoms to which it is attached and the remainder of ring E forms a naphthyl radical.

The cyclooxygenase-2 selective inhibitor may also be a compound of Formula (I) or pharmaceutically acceptable salt or prodrug thereof ; wherein: R2 is carboxyl; R3 is lower haloalkyl ; and each R4 is H, halo, lower alkyl, lower haloalkyl, lower haloalkoxy, lower alkylamino, amino, aminosulfonyl, lower alkylaminosulfonyl, 5-membered heteroarylalkylaminosulfonyl, 6-membered heteroarylalkylaminosulfonyl, lower aralkylaminosulfonyl, lower alkylsulfonyl, 6-membered nitrogen-containing heterocyclosulfonyl, optionally substituted phenyl, lower aralkylcarbonyl, or lower alkylcarbonyl; or wherein R4 together with ring E forms a naphthyl radical.

The cyclooxygenase-2 selective inhibitor may also be a compound of Formula (I) or pharmaceutically acceptable salt or prodrug thereof; wherein: n is an integer which is 0,1, 2,3 or 4 ;

is fluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, difluoromethyl, or trifluoromethyl; and each R4 is H, chloro, fluoro, bromo, iodo, methyl, ethyl, isopropyl, tert-butyl, butyl, isobutyl, pentyl, hexyl, methoxy, ethoxy, isopropyloxy, tertbutyloxy, trifluoromethyl, difluoromethyl, trifluoromethoxy, amino, N, N-dimethylamino, N, N- diethylamino, N-phenylmethylaminosulfonyl, N-phenylethylaminosulfonyl, N- (2- furylmethyl) aminosulfonyl, nitro, N, N-dimethylaminosulfonyl, aminosulfonyl, N- methylaminosulfonyl, N-ethylsulfonyl, 2, 2-dimethylethylaminosulfonyl, N, N- dimethylaminosulfonyl, N-(2-methylpropyl) aminosulfonyl, N-morpholinosulfonyl, methylsulfonyl, benzylcarbonyl, 2,2-dimethylpropylcarbonyl, phenylacetyl or phenyl; or wherein R4 together with the carbon atoms to which it is attached and the remainder of ring E forms a naphthyl radical.

The cyclooxygenase-2 selective inhibitor may also be a compound of Formula (I) or pharmaceutically acceptable salt or prodrug thereof ; wherein: n is an integer which is 0, 1, 2,3 or 4; R3 is trifluoromethyl or pentafluoroethyl; and each R4 is independently H, chloro, fluoro, bromo, iodo, methyl, ethyl, isopropyl, tert-butyl, methoxy, trifluoromethyl, trifluoromethoxy, N-phenylmethylaminosulfonyl, N-phenylethylaminosulfonyl, N- (2-furyhnethyl) aminosulfonyl, N, N- dimethylaminosulfonyl, N-methylaminosulfonyl, N- (2, 2-dimethylethyl) aminosulfonyl, dimethylaminosulfonyl, 2-methylpropylaminosulfonyl, N-morpholinosulfonyl, methylsulfonyl, benzylcarbonyl, or phenyl; or wherein R4 together with the carbon atoms to which it is attached and the remainder of ring E forms a naphthyl radical.

In yet another embodiment, the cyclooxygenase-2 selective inhibitor used in connection with the method (s) of the present invention can also be a compound having the structure of Formula (I) or pharmaceutically acceptable salt or prodrug thereof : wherein: n=4 ; G is 0 or S ; is H; is C02H ; is lower haloalkyl ;

a first R4 corresponding to R9 is hydrido or halo; a second R4 corresponding to Rl° is H, halo, lower alkyl, lower haloalkoxy, lower alkoxy, lower aralkylcarbonyl, lower dialkylaminosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, 5-membered nitrogen- containing heterocyclosulfonyl, or 6-membered nitrogen-containing heterocyclosulfonyl ; a third R4 corresponding to Roll ils H, lower alkyl, halo, lower alkoxy, or aryl; and a fourth R4 corresponding to R12 is H, halo, lower alkyl, lower alkoxy, and aryl; wherein Formula (I) is represented by Formula (Ia) : The cyclooxygenase-2 selective inhibitor used in connection with the method (s) of the present invention can also be a compound of having the structure of Formula (Ia) or pharmaceutically acceptable salt or prodrug thereof; wherein: R8 is trifluoromethyl or pentafluoroethyl; R9 is H, chloro, or fluoro ; Rl° is H, chloro, bromo, fluoro, iodo, methyl, tert-butyl, trifluoromethoxy, methoxy, benzylcarbonyl, dimethylaminosulfonyl, isopropylaminosulfonyl, methylaminosulfonyl, benzylaminosulfonyl, phenylethylaminosulfonyl, methylpropylaminosulfonyl, methylsulfonyl, or morpholinosulfonyl ; Rll is H, methyl, ethyl, isopropyl, tert-butyl, chloro, methoxy, diethylamino, or phenyl; and R12 is H, chloro, bromo, fluoro, methyl, ethyl, tert-butyl, methoxy, or phenyl.

Examples of exemplary chromene cyclooxygenase-2 selective inhibitors are depicted in Table lx below.

Table 1x Examples of Chromene Cyclooxygenase-2 Selective Inhibitors as Embodiments Compound Number Structural Formula B-3 o 02N - oh O CF3 6-Nitro-2-trifluoromethyl-2H-1 -benzopyran-3-carboxylic acid B_4 0 ci oh O CF3 0 CF3 6-Chloro-8-methyl-2-trifluoromethyl -2H-l-benzopyran-3-carboxylic acid B-5 0 cri SOH O CF3 ( (S)-6-Chloro-7- (1, 1-dimethylethyl)-2- (trifluo romethyl-2H-1-benzopyran-3-carboxylic acid Compound Number Structural Formula B-6 OH iso CF3 2-Trifluoromethyl-2H-naphtho [2, 3-b] pyran-3-carboxylic acid B-7 O \ OH /O/O-_CF 3 6-Chloro-7- (4-nitrophenoxy)-2- (trifluoramethyl)-2H-1- benzopyran-3-carboxylic acid B-8 0 Cl Cl /O CF3 Cl ((S)-6, 8-Dichloro-2-(trifluoromethyl)- 2H-1-benzopyran-3-carboxylic acid Compound Number Structural Formula _ I cri l OH 0 CF3 6-Chloro-2- (trifluoromethyl)-4-phenyl-2H- 1-benzopyran-3-carboxylic acid Buzz 0 , OH HO 0 CF3 6- (4-Hydroxybenzoyl)-2- (trifluoromethyl) -2H-1-benzopyran-3-carboxylic acid B-1 1 0 S F3C I OH s CF3 2-(Trifluoromethyl)-6-[(trifluoromethyl) thio] -2H-1-benzothiopyran-3-carboxylic acid Compound Number Structural Formula B-12 o cl SOH Cl cl 6, 8-Dichloro-2-trifluoromethyl-2H-1- benzothiopyran-3-carboxylic acid B-13 0 OH S CF-i 6- (1, 1-Dimethylethyl)-2- (trifluoromethyl) -2H-1-benzothiopyran-3-carboxylic acid B-14 0 Oh Oh F N CF3 6, 7-Difluoro-1, 2-dihydro-2- (trifluoro methyl)-3-quin. olinecarboxylic acid Compound Number Structural Formula B-15 0 Ci SOH N CF3 CH3 6-Chloro-1, 2-dihydro-l-methyl-2-(trifluoro methyl)-3-quinolinecarboxylic acid B-16 o ci OH N N CF3 6-Chloro-2- (trifluoromethyl)-1, 2-dihydro [1, 8] naphthyridine-3-carboxylic acid B-17 o ci OH CF3 ((S)-6-Chloro-1, 2-dihydro-2-(trifluoro methyl)-3-quinolinecarboxylic acid In a further embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof is selected from the class of tricyclic cyclooxygenase-2 selective inhibitors represented by the general structure of Formula II :

wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings; wherein R, is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein Ri is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; wherein R2 is selected from the group consisting of methyl or amino; and wherein R3 is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N- aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N- aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N- arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl ; or a pharmaceutically acceptable salt thereof.

In another embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof represented by the above Formula II

is selected from the group of compounds, illustrated in Table 2x, consisting of celecoxib (B-18; U. S. Patent No. 5,466, 823; CAS No. 169590-42-5), valdecoxib (B-19 ; U. S.

Patent No. 5,633, 272; CAS No. 181695-72-7), deracoxib (B-20; U. S. Patent No.

5,521, 207; CAS No. 169590-41-4), rofecoxib (B-21; CAS No. 162011-90-7), etoricoxib (MK-663 ; B-22; PCT publication WO 98/03484), JTE-522 (B-23), or pharmaceutically acceptable salt or prodrug thereof.

Table 2x Examples of Tricyclic Cyclooxygenase-2 Selective Inhibitors as Embodiments Compound Number Structural Formula B-18 oX// B-1 g \SOO CH H N / han N NEZ CF3 B-19 'S H2N / H3C 0/ H3C p B-20 O S/O OCH HaNi / N CHF2 Compound Number Structural Formula B-21 B-21 si 0 B-22 o<//o p/ O B-22 < CH3 H3C s CH3 IT '\N C1/ B-23 Cl H2N 0 N pin CHEZ

In still another embodiment, the cyclooxygenase-2 selective inhibitor is selected from the group consisting of celecoxib, rofecoxib and etoricoxib.

In yet another embodiment, the cyclooxygenase-2 selective inhibitor is parecoxib (B-24, U. S. Patent No. 5,932, 598, CAS No. 198470-84-7), which is a therapeutically effective prodrug of the tricyclic cyclooxygenase-2 selective inhibitor valdecoxib, B-19, may be advantageously employed as a source of a cyclooxygenase inhibitor (US 5,932, 598, herein incorporated by reference).

One form of parecoxib is sodium parecoxib.

In another preferred embodiment of the invention, the compound having the formula B-25 that has been previously described in International Publication number WO 00/24719 (which is herein incorporated by reference) is another tricyclic cyclooxygenase-2 selective inhibitor which may be advantageously employed.

Another cyclooxygenase-2 selective inhibitor that is useful in connection with the method (s) of the present invention is N- (2-cyclohexyloxynitrophenyl)-methane sulfonamide (NS-398) having a structure shown below as B-26.

In yet a further embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof used in connection with the method (s) of the present invention can be selected from the class of phenylacetic acid derivative cyclooxygenase-2 selective inhibitors represented by the general structure of Formula (III) : wherein R16 is methyl or ethyl; Rl7 is chloro or fluoro; Rlg is hydrogen or fluoro; Rl9 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; Ro is hydrogen or fluoro; and Rl is chloro, fluoro, trifluoromethyl or methyl, provided that R17, R18, Rl9 and R20 are not all fluoro when R16 is ethyl and R19 is H.

Another phenylacetic acid derivative cyclooxygenase-2 selective inhibitor used in connection with the method (s) of the present invention is a compound that has the designation of COX 189 (B-211) and that has the structure shown in Formula (III) or pharmaceutically acceptable salt or prodrug thereof, wherein: R16 is ethyl; Rl7 and Rl9 are chloro; R18 and R20 are hydrogen; and and Wl is methyl.

In yet another embodiment, the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof is represented by Formula (IV) :

wherein: X is O or S; J is a carbocycle or a heterocycle; R22 is NHSO2CH3 or F ; R23 is H, NO2, or F ; and R24 is H, NHSO2CH3, or (SO2CH3) C6H4.

According to another embodiment, the cyclooxygenase-2 selective inhibitors used in the present method (s) have the structural Formula (V) :

or pharmaceutically acceptable salt or prodrug thereof, wherein: T and M independently are phenyl, naphthyl, a radical derived from a heterocycle comprising 5 to 6 members and possessing from 1 to 4 heteroatoms, or a radical derived from a saturated hydrocarbon ring having from 3 to 7 carbon atoms; Ql, Q2, Ll or L2 are independently hydrogen, halogen, lower alkyl having from 1 to 6 carbon atoms, trifluoromethyl, or lower methoxy having from 1 to 6 carbon atoms; and

at least one of Ql, Q2, Ll or L2 is in the para position and is-S (O) n-R, wherein n is 0,1, or 2 and R is a lower alkyl radical having 1 to 6 carbon atoms or a lower haloalkyl radical having from 1 to 6 carbon atoms, or an-SO2NH2 ; or, Q 1 and Q2 are methylenedioxy; or Li and L2 are methylenedioxy; and R25, R26, R27, and R28 are independently hydrogen, halogen, lower alkyl radical having from 1 to 6 carbon atoms, lower haloalkyl radical having from 1 to 6 carbon atoms, or an aromatic radical selected from the group consisting of phenyl, naphthyl, thienyl, furyl and pyridyl ; or, R2s and R26 are O ; or, R27 and W8 are O ; or, R25, R26, together with the carbon atom to which they are attached, form a saturated hydrocarbon ring having from 3 to 7 carbon atoms; or, R27, R28, together with the carbon atom to which they are attached, form a saturated hydrocarbon ring having from 3 to 7 carbon atoms.

In another embodiment, the compounds N- (2- cyclohexyloxynitrophenyl) methane sulfonamide, and (E)-4- [ (4- methylphenyl) (tetrahydro-2-oxo-3-furanylidene) methyl] benzenesulfonamide having the structure of Formula (V) are employed as cyclooxygenase-2 selective inhibitors.

In a further embodiment, compounds that are useful for the cyclooxygenase-2 selective inhibitor or pharmaceutically acceptable salt or prodrug thereof in connection with the method (s) of the present invention, the structures for which are set forth in Table 3x below, include, but are not limited to: 6-chloro-2-trifluoromethyl-2H-l-benzopyran-3-carboxylic acid (B-27); 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-28); 8- (1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid (B-29); 6-chloro-8- (1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid (B-30) ; 2-trifluoromethyl-3H-naphtho [2, 1-b] pyran-3-carboxylic acid (B-31) ; 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-ca rboxylic acid (B-32); 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-33); 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-34);

6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carbo xylic acid (B-35); 5, 7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-36); 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-37); 7, 8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-38); 6,8-bis (dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid (B-39) ; 7- (1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid (B-40); 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-41); 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-42) ; 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-43); 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-44); 6, 7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-45); 6, 8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-46); 6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-47); 8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-48) 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carbo xylic acid (B-49); 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-50); 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-51); 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-52); 8-bromo-5-fluoro-2-trifluoromethyl-2H-l-benzopyran-3-carboxy lic acid (B-53); 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-54) ; 6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-55); <BR> <BR> <BR> <BR> 6-[[(phenylmethyl) amino] sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-56); <BR> <BR> <BR> 6-[(dimethylamino) sulfonyl]-2-trifluoromethyl-2H-l-benzopyran-3-carboxylic acid<BR> <BR> <BR> <BR> <BR> (B-57) ; 6-[(methylamino) sulfonyl]-2-trifluoromethyl-2H-l-benzopyran-3-carboxylic acid <BR> <BR> <BR> <BR> (B-58) ;<BR> <BR> <BR> <BR> <BR> <BR> 6- [ (4-morpholino) sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-59); 6- [ (1, 1-dimethylethyl) aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxyli c acid (B-60); <BR> <BR> <BR> 6-[(2-methylpropyl) aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxyli c acid (B-61);

6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-62); 8-chloro-6-[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl -2H-1-benzopyran-3- carboxylic acid (B-63); 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxyli c acid (B-64); 6, 8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-65); 8-chloro-5, 6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-66); 6, 8-dichloro- (S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-67); 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-68); 6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1- benzopyran-3-carboxylic acid (B-69); <BR> <BR> <BR> <BR> 6-[[N-(2-phenylethyl) amino] sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-70); 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid (B-71); 7- (1, 1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carbox ylic acid (B-72); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (B-73); 3-[(3-Chloro-phenyl)-(4-methanesulfonyl-phenyl)-methylene]-d ihydro-furan-2-one or BMS-347070 (B-74); 8-acetyl-3- (4-fluorophenyl)-2- (4-methylsulfonyl) phenyl-imidazo (1, 2-a) pyridine (B-75); 5, 5-dimethyl-4-(4-methylsulfonyl)phenyl-3-phenyl-2-(5H)-furano ne (B-76); 5- (4-fluorophenyl)-1- [4- (methylsulfonyl) phenyl]-3- (trifluoromethyl) pyrazole (B-77); 4-(4-fluoroiphenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3- (trifluoromethyl) pyrazole (B-78); 4- (5- (4-chlorophenyl)-3- (4-methoxyphenyl)-lH-pyrazol-1-yl) benzenesulfonamide (B- 79); 4- (3, 5-bis (4-methylphenyl)-lH-pyrazol-l-yl) benzenesulfonamide (B-80); 4- (5- (4-chlorophenyl)-3-phenyl-lH-pyrazol-1-yl) benzenesulfonamide (B-81); 4- (3, 5-bis (4-methoxyphenyl)-lH-pyrazol-l-yl) benzenesulfonamide (B-82); 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-lH-pyrazol-l-yl) benzenesulfonamide (B-83); 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-lH-pyrazol-l-yl) benzenesulfonamide (B-84); 4-(5-(4-chloroiphenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-y l)benzenesulfonamide (B- 85); 4- (4-chloro-3, 5-diphenyl-lH-pyrazol-1-yl) benzenesulfonamide (B-86); 4- [5- (4-chlorophenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-87);

4- [5-phenyl-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-88) ; 4- [5- (4-fluorophenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-89); <BR> <BR> <BR> 4- [5- (4-methoxyphenyl)-3- (trifluoromethyl)-lH-pyrazol-l-yl] benzenesulfonamide (B- 90); 4- [5- (4-chlorophenyl)-3- (difluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-91); 4- [5- (4-methylphenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-92); 4- [4-chloro-5- (4-chlorophenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (B-93) ; 4- [3- (difluoromethyl)-5- (4-methylphenyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-94) ; 4- [3- (difluoromethyl)-5-phenyl-lH-pyrazol-1-yl] benzenesulfonamide (B-95); <BR> <BR> <BR> <BR> 4- [3- (difluoromethyl)-5- (4-methoxyphenyl)-lH-pyrazol-1-yl] benzenesulfonamide (B- 96); 4- [3-cyano-5- (4-fluorophenyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-97); 4- [3- (difluoromethyl)-5- (3-fluoro-4-methoxyphenyl)-1H-pyrazol-1- yl] benzenesulfonamide (B-98); 4- [5- (3-fluoro-4-methoxyphenyl)-3- (trifluoromethyl)-1 H-pyrazol-1- yl] benzenesulfonamide (B-99); 4- [4-chloro-5-phenyl-lH-pyrazol-1-yl] benzenesulfonamide (B-100); 4- [5- (4-chlorophenyl)-3- (hydroxymethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-101); 4- [5- (4- (N, N-dimethylamino) phenyl)-3- (trifluoromethyl)-lH-pyrazol-1- yl] benzenesulfonamide (B-102); 5- (4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene (B-103); 4- [6- (4-fluorophenyl) spiro [2.4] hept-5-en-5-yl] benzenesulfonamide (B-104); 6- (4-fluorophenyl)-7- [4- (methylsulfonyl) phenyl] spiro [3.4] oct-6-ene (B-105) ; 5- (3-chloro-4-methoxyphenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hept-5-ene (B- 106); 4- [6- (3-chloro-4-methoxyphenyl) spiro [2.4] hept-5-en-5-yl] benzenesulfonamide (B-107); 5- (3, 5-dichloro-4-methoxyphenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene (B- 108); 5- (3-chloro-4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2.4] hept-5-ene (B-109); 4- [6- (3, 4-dichlorophenyl) spiro [2.4] hept-5-en-5-yl] benzenesulfonamide (B-110); 2- (3-chloro-4-fluorophenyl)-4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl) thiazole (B- 111) ;

2- (2-chlorophenyl)-4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl) thiazole (B-112) ; 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl)-2-methylthiazole (B-113) ; 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2-trifluoromethylthiazole (B-114) ; 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2- (2-thienyl) thiazole (B-115) ; 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2-benzylaminothiazole (B-116) ; 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2- (1-propylamino) thiazole (B-117) ; 2- [ (3, 5-dichlorophenoxy) methyl)-4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] thiazole (B-118) ; 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl)-2-trifluoromethylthiazole (B-119) ; 1-methylsulfonyl-4- [1, 1-dimethyl-4- (4-fluorophenyl) cyclopenta-2,4-dien-3-yl] benzene (B-120); 4- [4- (4-fluorophenyl)-1, 1-dimethylcyclopenta-2, 4-dien-3-yl] benzenesulfonamide (B- 121); 5- (4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hepta-4,6-diene (B-122); 4- [6- (4-fluorophenyl) spiro [2.4] hepta-4, 6-dien-5-yl] benzenesulfonamide (B-123); 6- (4-fluorophenyl)-2-methoxy-5- [4- (methylsulfonyl) phenyl]-pyridine-3-carbonitrile (B- 124); 2-bromo-6- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl]-pyridine-3-carbonitrile (B- 125); 6- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl]-2-phenyl-pyridine-3-carbonitrile (B- 126); <BR> <BR> <BR> <BR> 4- [2- (4-methylpyridin-2-yl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide (B-127); <BR> <BR> <BR> <BR> 4- [2- (5-methylpyridin-3-yl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide (B-128); <BR> <BR> <BR> <BR> 4- [2- (2-methylpyridin-3-yl)-4- (trifluoromethyl)-1H-imidazol-1-yl] benzenesulfonamide (B-129); 3- [l- [4- (methylsulfonyl) phenyl]-4- (trifluoromethyl)-lH-imidazol-2-yl] pyridine (B-130); 2- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)-lH-imidazol-2-yl] pyridine (B-131); <BR> <BR> <BR> <BR> 2-methyl-4- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)-lH-imidazol-2-yl] pyridine (B-132); <BR> <BR> <BR> <BR> 2-methyl-6- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)-lH-imidazol-2-yl] pyridine (B-133);

4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol- 1-yl]benzenesulfonamide (B-134); <BR> <BR> <BR> <BR> 2- (3, 4-difluorophenyl)-1- [4- (methylsulfonyl) phenyl]-4- (trifluoromethyl)-lH-imidazole (B-135); 4- [2- (4-methylphenyl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide (B- 136); 2- (4-chlorophenyl)-1- [4- (methylsulfonyl) phenyl]-4-methyl-lH-imidazole (B-137); 2- (4-chlorophenyl)-1- [4- (methylsulfonyl) phenyl]-4-phenyl-1H-imidazole (B-138); 2- (4-chlorophenyl)-4- (4-fluorophenyl)-1- [4- (methylsulfonyl) phenyl]-lH-imidazole (B- 139); 2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl-4-( trifluoromethyl)-1H- imidazole (B-140); 1- [4- (methylsulfonyl) phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole (B-141); 2- (4-methylphenyl)-1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazole (B- 142); 4- [2- (3-chloro-4-methylphenyl)-4- (trifluoromethyl)-1H-imidazol-1- yl] benzenesulfonamide (B-143); 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-( trifluoromethyl)-1H- imidazole (B-144); 4- [2- (3-fluoro-5-methylphenyl)-4- (trifluoromethyl)-1 H-imidazol-1- yl] benzenesulfonamide (B-145); 2- (3-methylphenyl)-1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazole (B- 146); 4- [2- (3-methylphenyl)-4-trifluoromethyl-lH-imidazol-1-yl] benzenesulfonamide (B- 147); 1- [4- (methylsulfonyl) phenyl]-2- (3-chlorophenyl)-4-trifluoromethyl-lH-imidazole (B- 148); 4- [2- (3-chlorophenyl)-4-trifluoromethyl-lH-imidazol-1-yl] benzenesulfonamide (B-149); 4-[2-phenyl-4-trifluoromethyl-lH-imidazol-l-yl] benzenesulfonamide (B-150); 4- [2- (4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1- yl] benzenesulfonamide (B-151) ; 1-allyl-4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-5- (trifluoromethyl)-lH- pyrazole (B-152);

4- [1-ethyl-4- (4-fluorophenyl)-5- (trifluoromethyl)-lH-pyrazol-3-yl] benzenesulfonamide (B-153); N-phenyl- [4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-5- (trifluoromethyl)-lH- pyrazol-1-yl] acetamide (B-154); ethyl [4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-5- (trifluoromethyl)-lH-pyrazol- l-yl] acetate (B-155); 4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-1- (2-phenylethyl)-1H-pyrazole (B- 156); 4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-1- (2-phenylethyl)-5- (trifluoromethyl) pyrazole (B-157); 1-ethyl-4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-5- (trifluoromethyl)-lH- pyrazole (B-158); 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl)-2-trifluoromethyl-lH-imidazole (B-159); 4- [4- (methylsulfonyl) phenyl]-5- (2-thiophenyl)-2- (trifluoromethyl)-lH-imidazole (B- 160); 5- (4-fluorophenyl)-2-methoxy-4- [4- (methylsulfonyl) phenyl]-6- (trifluoromethyl) pyridine (B-161); <BR> <BR> <BR> <BR> 2-ethoxy-5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl]-6- (trifluoromethyl) pyridine (B-162); 5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl]-2- (2-propynyloxy)-6- (trifluoromethyl) pyridine (B-163); 2-bromo-5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl]-6- (trifluoromethyl) pyridine (B-164); 4- [2- (3-chloro-4-methoxyphenyl)-4, 5-difluorophenyl] benzenesulfonamide (B-165); 1- (4-fluorophenyl)-2- [4- (methylsulfonyl) phenyl] benzene (B-166) ; 5-difluoromethyl-4- (4-methylsulfonylphenyl)-3-phenylisoxazole (B-167); 4- [3-ethyl-5-phenylisoxazol-4-yl] benzenesulfonamide (B-168) ; 4- [5-difluoromethyl-3-phenylisoxazol-4-yl] benzenesulfonamide (B-169); 4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide (B-170) ; 4- [5-methyl-3-phenyl-isoxazol-4-yl] benzenesulfonamide (B-171); 1- [2- (4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-172); 1- [2- (4-fluoro-2-methylphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-173); 1- [2- (4-chlorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-174) ;

1- [2- (2, 4-dichlorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-175) ; 1- [2- (4-trifluoromethylphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-176) ; 1- [2- (4-methylthiophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-177) ; 1- [2- (4-fluorophenyl)-4, 4-dimethylcyclopenten-1-yl]-4- (methylsulfonyl) benzene (B- 178); 4- [2- (4-fluorophenyl)-4, 4-dimethylcyclopenten-1-yl] benzenesulfonamide (B-179); 1- [2- (4-chlorophenyl)-4, 4-dimethylcyclopenten-1-yl]-4- (methylsulfonyl) benzene (B- 180); 4- [2- (4-chlorophenyl)-4, 4-dimethylcyclopenten-1-yl] benzenesulfonamide (B-181); 4- [2- (4-fluorophonyl) cyclope-nten-1-yl] benzenesulfonamide (B-182); 4- [2- (4-chlorophenyl) cyclopenten-1-yl] benzenesulfonamide (B-183) ; 1- [2- (4-methoxyphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-184); 1- [2- (2, 3-difluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-185); 4- [2- (3-fluoro-4-methoxyphenyl) cyclopenten-1-yl] benzenesulfonamide (B-186); 1- [2- (3-chloro-4-methoxyphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene (B-187); 4- [2- (3-chloro-4-fluorophenyl) cyclopenten-1-yl] benzenesulfonamide (B-188); 4- [2- (2-methylpyridin-5-yl) cyclopenten-1-yl] benzenesulfonamide (B-189); ethyl 2- [4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazol-2-yl]-2-benzyl-acetate (B-190); 2- [4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] acetic acid (B-191) ; 2- (tert-butyl)-4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazole (B-192) ; 4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] -2-phenyloxazole (B-193) ; 4- (4-fluorophenyl)-2-methyl-5- [4- (methylsulfonyl) phenyl] oxazole (B-194); 4- [5- (3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl] benzenesulfonamide (B- 195); 6-chloro-7- (1, 1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid (B-196); 6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid (B-197); 5, 5-dimethyl-3-(3-fluorophenyl)-4-methylsulfonyl-2(5H)-furanon e (B-198); 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid (B-199); 4- [5- (4-chlorophenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B-200); 4- [5- (4-methylphenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide (B- 201);

4- [5- (3-fluoro-4-methoxyphenyl)-3- (difluoromethyl)-lH-pyrazol-1- yl] benzenesulfonamide (B-202); 3- [1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazol-2-yl] pyridine (B-203); 2-methyl-5- [1- [4-(methylsulfonyl) phenyl]-4-trifluoromethyl-1 H-imidazol-2-yl] pyridine (B-204); <BR> <BR> <BR> 4- [2- (5-methylpyridin-3-yl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide (B-205); 4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide (B-206); 4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide (B-207); [2-trifluoromethyl-5- (3, 4-difluorophenyl) -4-oxazolyl] benzenesulfonamide (B-208); 4- [2-methyl-4-phenyl-5-oxazolyl] benzenesulfonamide (B-209); 4- [5- (2-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl] benzenesulfonamide (B- 210); [2- (2-chloro-6-fluoro-phenylamino)-5-methyl-phenyl]-acetic acid or COX 189 (B-211) ; N- (4-Nitro-2-phenoxy-phenyl)-methanesulfonamide or nimesulide (B-212); N-[6-(2, 4-difluoro-phenoxy)-1-oxo-indan-5-yl]-methanesulfonamide or flosulide (B- 213); N-[6-(2, 4-Difluoro-phenylsulfanyl)-1-oxo-1 H-inden-5-yl]-methanesulfonamide, soldium salt or L-745337 (B-214); N- [5- (4-fluoro-phenylsulfanyl)-thiophen-2-yl]-methanesulfonamide or RWJ-63556 (B- 215); 3- (3, 4-Difluoro-phenoxy)-4- (4-methanesulfonyl-phenyl)-5-methyl-5- (2, 2, 2-trifluoro- ethyl)-5H-furan-2-one or L-784512 or L-784512 (B-216); (5Z)-2-amino-5-[[3, 5-bis (l, 1-dimethylethyl)-4-hydroxyphenyl] methylene] -4 (5H)- thiazolone or darbufelone (B-217); CS-502 (B-218) ; LAS-34475 (B-219); LAS-34555 (B-220); S-33516 (B-221); SD-8381 (B-222); L-783003 (B-223); <BR> <BR> <BR> N- [3- (formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanes ulfonamide or T-614 (B-224);

D-1367 (B-225); L-748731 (B-226); (6aR, 1 OaR)-3-(1, 1-dimethylheptyl)-6a, 7,10, 10a-tetrahydro-1-hydroxy-6, 6-dimethyl-6H- dibenzo [b, d] pyran-9-carboxylic acid or CT3 (B-227); CGP-28238 (B-228); 4- [ [3, 5-bis (l, l-dimethylethyl)-4-hydroxyphenyl] methylene] dihydro-2-methyl-2H-1, 2- oxazin-3 (4H)-one orBF-389 (B-229); GR-253035 (B-230); 6-dioxo-9H-purin-8-yl-cinnamic acid (B-231); S-2474 (B-232); 4- [4- (methyl)-sulfonyl) phenyl]-3-phenyl-2 (5H) -furanone; 4- (5-methyl-3-phenyl-4-isoxazolyl) ; 2- (6-methylpyrid-3-yl)-3- (4-methylsulfonylphenyl)-5-chloropyridine ; 4- [5- (4-methylphenyl)-3- (trifluoromethyl)-lH-pyrazol-l-yl], N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl] ; 4-[5-(3-fluoro-4-methoxyphenyl)-3-difluoromethyl)-1H-pyrazol -1- yl] benzenesulfonamide ; (S) -6, 8-dichloro-2- (trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid; 2- (3, 4-difluorophenyl)-4- (3-hydroxy-3-methylbutoxy)-5- [4- (methylsulfonyl) phenyl] - 3 (2H)-pyridzainone ; 2-trifluoromethyl-3H-naptho [2, 1-b] pyran-3-carboxylic acid ; 6-chloro-7-(1, 1-dimethylethyl)-2-kifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid; [2- (2, 4-dichloro-6-ethyl-3, 5-dimethyl-phenylamino)-5-propyl-phenyl]-acetic acid.

Table 3x-Examples of Cyclooxygenase-2 Selective Inhibitors as Embodiments Compound Structural Formula Number o- O-N+ 0 B-26 HN \ O N- (2-cyclohexyloxynitrophenyl) methane sulfonamide or NS-398 ; 0 cul O B-27 F 0 F F 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 ce OH B-28 F F F F 6-chloro-7-methyl-2-trifluoromethyl-2H-l-benzopyran-3-carbox yiic acid ; Compound Structural Formula Number o 0 'F F \F % \ F F 8- (1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid ; ce 0 0 B-30 H (ruz Ho 0 6-chloro-8- (1-methylethyl)-2-trifluoromethyl - 2H-1-benzopyran-3-carboxylic acid ; F F F HA B-31 2-trifluoromethyl-3H-naphtho [2, 1-b] pyran-3-carboxylic acid ; Compound Compound Structural Formula Number o- oh B-32 F 0 F F 7- (1, 1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; 0 Br OH B-33 F O 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; cri F4 0 B-34 F \ F O OH 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 F O Fox F F I B-35 F F F 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carbo xylic acid ; Compound Structural Formula Number ci 0 . oH B-3 6 F ou F F 5, 7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 O oh B-37 F F F 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; ~ o zou I F B-38 zozo F F 7, 8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; Compound Structural Formula Number OOH F \F O B-39 \ 6, 8-bis (dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid ; o OH (/F B-4 (7/O F F 7- (1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxyl ic acid ; F F F HA O B-41 0 7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 ci OH B-42 F F 0 F F 6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; Compound Structural Formula Number \ cl / 0 B-43 FxJs F F HO 6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; 0 ce OH I F B-44 0 F F 6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid ; 0 ce OH B-45 cl 0 F also F F 6, 7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 ce SOH O I F B-46 9 JFXF F F CL 6, 8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 45 Compound Structural Formula Number o- ce zou B-47 F / B-47 F 6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid ; 0 zon FI B-48 Ci F F CL 8-chloro-6-methyl-2-trifluoromethyl-2H-l-benzopyran-3-carbox ylic acid ; o oN I F B-49/ po F F CI 8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carbo xylic acid ; o Br zou I F Bozo F F cri 6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; Compound Structural Formula Number o- OU F F Ber F F Ber 8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; 0 o I F B-52 0 XF BER ber 8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; Bu 0 F F B-53/ F IF HO 8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; 0 ce OH I F B-54 9\ F F F F F 6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carbox ylic acid ; Compound Structural Formula Number O \ Br 0 B-55 X f F F ZOZO 6-bromo-8-methoxy-2-trifluoromethyl-2H-l-benzopyran-3-carbox ylic acid ; F 0 F OH 0 Zu B-56 js 0 H 6-[[(phenylmethyl) amino] sulfonylJ-2-trifluoromethyl-2H-I-benzopyran-3-carboxylic acid ; F F O F I HO \ O B-57 N 0 6- [ (dimethylamino) sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; Compound Structural Formula Number F F 0 0 Ho 13-58 s 0 0 H 6-[(methylamino) sulfonyl]-2-trifluoromethyl-2H-I-benzopyran-3-carboxylic acid ; F F F 0 OH B-59 \ Zu 0 6- [ (4-morpholino) sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; HN ou po 0 B-60 HO F If F F 6- [ (1, 1-dimethylethyl) aminosulfonyl]-2-trifluoromethyl -2H-l-benzopyran-3-caTboxylic acid ; Compound Structural Formula Number F F O 0 ho HO 0 O N 0 H 6- [ (2-methylpropyl) aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxyli c acid ; ZU 0 0 HO I O B-62 \ o 6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; 11 OaSX a'' s 0 \OH 0 B-63 o F C1 F 8-chloro-6- [ [ (phenylmethyl) amino] sulfonyl]-2-trifluoromethyl- 2H-1-benzopyran-3-carboxylic acid ; F F O O HO B-64 H \ \ \ 6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxyli c acid ; Compound Structural Formula Number o _ Br OU F 13-65 0 Ber Bu 6, 8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; o- zou B-66 F 'o Ci CI 8-chloro-5, 6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; 0 ce 'OH B-67 'o F F ce 6, 8-dichloro- (S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; Fi. 1 0 F O B-68 ho _ _ o/ 0 6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxy lic acid ; Compound Structural Formula Number F 0 F I HA HO ° H 1 6-[rN-(2-furylmethyl) amino] sulfonyl]-2-trifluoromethyl -2H-l-benzopyran-3-carboxylic acid ; F F 0 Ho 0 HO S \O B-7 O H 6-[[N-(2-phenylethyl) aminoAsulfonyl]-2-trifluoromethyl-2H-l-benzopyran - 3-carboxylic acid ; O I OH B-71 F 0 F F F F 6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid ; Compound Compound Structural Formula Number F F O B-72 F F F' O OU 7- (l, l-dimethylethyl)-2-pentafluoroethyl-2H - 1-benzopyran-3-carboxylic acid ; 0 ci oH B-73 F s F F 6-chloro-2-trifluoromethyl-2H-l-benzothiopyran-3-carboxylic acid ; Me OI O 1 < 0 0 3- [ (3-chloro-phenyl)- (4-methanesulfonyl-phenyl)-methylene] - dihydro-furan-2-one or BMS-347070 ; Compound Structural Formula Number o N NU O 0 8-acetyl-3- (4-fluorophenyl)-2- (4-methylsulfonyl) phenyl-imidazo (1, 2-a) pyridine ; 0 0 Bu 5, S-dimethyl-4-(4-methylsulfonylphenyl-3-phenyl-2-(SH)-furanon e ; F F F A B-77 B-77 0 F 5- (4-fluorophenyl)-1- [4- (methylsulfonyl) phenyl]-3- (trifluoromethyl) pyrazole ; Compound Compound Structural Formula Number F F 0 F B-78 N N u 4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] - 1-phenyl-3- (trifluoromethyl) pyrazole ; ci 0 O B-79 N S-NH2 N 11 u o 4- (5- (4-chlorophenyl)-3- (4-methoxyphenyl)-1H-pyrazol-1-yl) benzenesulfonamide ; Compound Structural Formula Number N Nez l d H2N 0 4- (3, 5-bis (4-methylphenyl)-IH-pyrazol-1-yl) benzenesulfonamide ; C N N H N/p CI 0--l 4-(5-(4-chlorophenyl)-3-phenyl-lH-pyrazol-l-yl) benzenesulfonamide ; Compound Structural Formula Number o NEZ B-82 ou S\\ O HN'0 4- (3, 5-bis (4-methoxyphenyl)-lTI-pyrazol-l-yl) benzenesulfonamide ; N B-83 ou /cri ci 4- (5- (4-chlorophenyl)-3- (4-methylphenyl)-1 H-pyrazol-1-yl) benzenesulfonamide ; Compound Structural Formula Number NP N/ O_ B-84 N/ cri 4- (5- (4-chlorophenyl)-3- (4-nitrophenyl)-1 H-pyrazol-1-yl) benzenesulfonamide ; cl O B-85 i/\ N' II-NH s N ci 4- (5- (4-chlorophenyl)-3- (5-chloro-2-thienyl)-lH-pyrazol-1-yl) benzenesulfonamide ; / Gon cri 0 B-8E) N \ II-NHz N N / 4- (4-chloro-3, 5-diphenyl-1H-pyrazol-1-yl) benzenesulfonamide ; Compound Structural Formula Number F F-F N B-87 Zu /cl H\ 4- [5- (4-chlorophenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; / O B-88 II-NHZ F -N N F F 4- [5-phenyl-3- (trifluoromethyl)- IH-pyrazol-1-yl] benzenesulfonamide ; F F--F N B-89 ) Q HN HzN O 4- [5- (4-fluorophenyl)-3- (trifluoromethyl)-IH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F-F NEZ B-90 Po HAN 4 [5- (4-methoxyphenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; F F N6/ N B-91 ci HaN O 4- [5- (4-chlorophenyl)-3- (difluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; F F-F N IZ-1 N H N/\° z 4- [5- (4-methylphenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F- F IF ZON C1 ci I B-93 X o//NH2 C ! cri 4- [4-chloro-5- (4-chlorophenyl)-3- (trifluoromethyl)-IH-pyrazol-1-yl] benzenesulfonamide ; F F B-94 ors B-94 S H2N ° 4- [3- (difluoromethyl)-5- (4-methylphenyl)-lH-pyrazol-1-yl] benzenesulfonamide ; / O 11 B-95 N II-NHz FUN F 4- [3- (difluoromethyl)-5-phenyl-lH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F N B-96 F F H2N 4- [3- (difluoromethyl)-5- (4-methoxyphenyl)-lH-pyrazol-1-yl] benzenesulfonamide ; N N N F Ow F H2N ° 4- [3-cyano-5- (4-fluorophenyl)-IH-pyrazol-1-yl] benzenesulfonamide ; F F \N N B-98 F 0 /s'O ors 0'NH 4- [3- (difluoromethyl)-5- (3-fluoro-4-methoxyphenyl)-lH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F F N N B-99 F po //S O \ O NHZ 4- [5- (3-fluoro-4-methoxyphenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; N cri 0 N HAN \ 4- [4-chloro-5-phenyl-lH-pyrazol-1-yl] benzenesulfonamide ; HO N B-101 O Cl Qcl han 4- [5- (4-chlorophenyl)-3- (hydroxymethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F F N/ N B-102 - 6 Nu H N \ /U% 0 1 H2N/ 4- [5- (4- (N, N-dimethylamino) phenyl)-3- (trifluoromethyl) - 1H-pyrazol-1-yl] benzenesulfonamide ; \S4O 08S B-103 F 5- (4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hept-5-ene ; Compound Structural Formula Number w < 0 XF B-104 o_s o I NHz 4- [6- (4-fluorophenyl) spiro [2. 4] hept-5-en-5-yl] benzenesulfonamide ; F B-105 11 T 6- (4-fluorophenyl)-7- [4-methylsulfonyl) phenyl] spiro [3. 4] oct-6-ene ; 0 X B-106 0 \\ \\ 0 5- (3-chloro-4-methoxyphenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hept-5-ene ; Compound Structural Formula Number ou cl B-IO O 4- [6- (3-chloro-4-methoxyphenyl) spiro [2. 4] hept-5-en-5-yl] benzenesulfonamide ; s- ou ci CI B-108 ß CL ce 5- (3, 5-dichloro-4-methoxyphenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hept-5-ene ; cl F fez B-109 0 0 0 5- (3-chloro-4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hept-5-ene ; Compound Structural Formula Number ci cl te B-110 0 HZN--I I 4- [6- (3, 4-dichlorophenyl) spiro [2. 4] hept-5-en-5-yl] benzenesulfonamide ; F N zu F cul 0 s po 2- (3-chloro-4-fluorophenyl)-4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl) thiazole ; N / N B-1 12 1 s ci ci 2- (2-chlorophenyl)-4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl) thiazole ; Compound Structural Formula Number P---- s S B-113 0\S /\o 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl)-2-methylthiazole ; \ s 0 0 B-114 tX /s F \N/ F F F 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2-trifluoromethylthiazole ; Compound Structural Formula Number oV o s B-115 F X // s/ F I' S 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2- (2-thienyl) thiazole ; /F N Ho B-1 16 cor 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2-benzylaminothiazole ; W O \s B-117 s F N N I H 4- (4-fluorophenyl)-5- (4-methylsulfonylphenyl)-2- (l-propylamino) thiazole ; Compound Structural Formula Number ci N Cl \S /cri CI 2- ( (3, 5-dichlorophenoxy) methyl)-4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] thiazole ; F / S F F B-1 19 N zu 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl)-2-trifluoromethylthiazole ; 0=so i B-120 F 1-methylsulfonyl-4- [1, 1-dimethyl-4- (4-fluorophenyl) cyclopenta-2, 4-dien-3-yl] benzene ; Compound Structural Formula Number 0 HaN-II H2N-S 11- B-121 F F 4- [4- (4-fluorophenyl)-1, 1-dimethylcyclopenta-2, 4-dien-3-yl] benzenesulfonamide ; 0 B-122 B-122 F i V 5- (4-fluorophenyl)-6- [4- (methylsulfonyl) phenyl] spiro [2. 4] hepta-4, 6-diene ; F B-123 NHz NHZ NH2 4- [6- (4-fluorophenyl) spiro [2. 4] hepta-4, 6-dien-5-yl] benzenesulfonamide ; Compound Structural Formula Number U XsX B-124 S M B-124 6- (4-fluorophenyl)-2-methoxy-5- [4- (methylsulfonyl) phenyl] -pyridine-3-carbonitrile ; F \\su F, B-125 NEZ Br 2-bromo-6- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] - pyridine-3-carbonitrile ; Compound Structural Formula Number F /Q _ F B-126 N 6- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl]-2-phenyl-pyridine-3-carbonitrile ; \ zon 11 N B-127 N HzN II N F F F F F 4- [2- (4-methylpyridin-2-yl)-4- (trifluoromethyl)-lH-imidazol-l-yl] benzenesulfonamide ; N ION ZON B-1 Z HZN, I I N F F F F 4- [2- (5-methylpyridin-3-yl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number \N- 0 ZON B-129 HzN-li N F 11 Fuzz F F 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-lH-imidazol- 1-yl] benzenesulfonamide ; \N N B-130 N NIF F F F 3- [I- [4- (methylsulfonyl) phenyl]-4- (trifluoromethyl)-lH-imidazol-2-yl] pyridine ; S pF _ 0 F 0 NI F B-131 O clef 2- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)]-lH-imidazol-2-yl] pyndine ; Compound Structural Formula Number 7 zu N F N B-132 /\ 2-methyl-4- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)] -lH-imidazol-2-yl] pyridine ; \S F F 0 F N F N B-133 N 2-methyl-6- [1- [4- (methylsulfonyl) phenyl-4- (trifluoromethyl)] -lH-imidazol-2-yl] pyridine ; F F IF NHZ ZON \ B-134 N1 % jN o \ NH 4- [2- (6-methylpyridin-3-yl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F 0 s B-135 \ F F F F F F 2- (3, 4-difluorophenyl)-1- [4- (methylsulfonyl) phenyl] -4- (trifluoromethyl)-lH-imidazole ; F F F J N B-136 NHZ NH 4- [2- (4-methylphenyl)-4- (trifluoromethyl)-lH-imidazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number N \N B-137 Cil asz ors 2- (4-chlorophenyl)-I- [4- (methylsulfonyl) phenyl]-4-methyl-IH-imidazole ; N \ N B-138 | ClX Q B-138 Cil ors 2- (4-chlorophenyl)-1- [4- (methylsulfonyl) phenyl]-4-phenyl-1 H-imidazole ; Compound Structural Formula Number ci cß fuzzy Zut N B-139 i F 2- (4-chlorophenyl)-4- (4-fluorophenyl)-1- [4- (methylsulfonyl) phenyl] - 1H-imidazole ; Zu F s N N B-140 $ N / O F 2- (3-fluoro-4-methoxyphenyl)-1- [4- (methylsulfonyl) phenyl -4-(trifluoromethyl)]-lH-imidazole ; _ B-141 11 N Fuzz II/F 0 F F 1- [4- (methylsulfonyl) phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole ; Compound Structural Formula Number F F IF Zu N \ B-142 2- (4-methylphenyl)-1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazole ; Cl \/NH2 0 N B-143 N F F F 4- [2- (3-chloro-4-methylphenyl)-4- (trifluoromethyl) -IH-imidazol-l-yl] benzenesulfonamide ; F \ S\/\ \\O 'b N B-144 W F F F 2- (3-fluoro-5-methylphenyl)-1- [4- (methylsulfonyl) phenyl] -4-(trifluoromethyl)-1 H-imidazole ; Compound Structural Formula Number F O /SNHz /\o N F F F F F 4- [2- (3-fluoro-5-methylphenyl)-4- (trifluoromethyl -1 H-imidazole-1-yl] benzenesulfonamide ; po zon B-146 N F O F F' 2- (3-methylphenyl)-1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazole ; \ B-147 B-147 F F F 4- [2- (3-methylphenyl)-4-trifluoromethyl-lH-imidazol-1-yl] benzenesulfonamide ; 4-[2-(3-methylphenyl)-4-trifluoromethyl-lH-imidazol-l-yl] benzenesulfonamide ; Compound Compound Structural Formula Number ci Zon B-148 11 -S N F F'' 1- [4- (methylsulfonyl) phenyl]-2- (3-chlorophenyl)-4-trifluoromethyl-lH-imidazole ci vs N B-149 11 F F F 4- [2- (3-chlorophenyl)-4-trifluoromethyl-lH-imidazol-1-yl] benzenesulfonamide ; 0-N X X N F XI 0 F F 4-[2-phenyl-4-trifluoromethyl-lH-imidazol-l-yl] benzenesulfonamide ; Compound Structural Formula Number -0 cri 0 NH2 zu N B-151/ N F-F F F 4- [2- (4-methoxy-3-chlorophenyl)-4-trifluoromethyl-IH-imidazol-1-y llbenzenesulfonamide ; 0 g NJ= N B-152 F F F 1-allyl-4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl) - 5- (trifluoromethyl)-1 H-pyrazole ; 0 N H2N X 6/>/N \N J B-153 N s B-153 \ F F F 4- [1-ethyl-4- (4-fluorophenyl)-5- (trifluoromethyl)-1 H-pyrazol-3-yl] benzenesulfonamide ; Compound Compound Structural Formula Number . 0 i B-154/o N F F F F N-phenyl- [4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phonyl] -5-(trifluoromethyl)-lH-pyrazol-1-yl] acetamide ; B-155 0 N I F F \ F ethyl [4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl] -5-(trifluoromethyl)-lH-pyrazol-l-yl] acetate ; Compound Structural Formula Number F . N 0 \ 4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl]-l- (2-phenylethyl)-lH-pyrazole ; SO B-157 N F F I F F 4- (4-fluorophenyl)-3- [4- (methylsulfonyl) phenyl] -1-(2-phenylethyl)-5-(trifluoromethyl) pyrazole ; o 0 s NJ // F B-158 F F F 1-ethyl-4 (4-fluorophenyl)-3- [4-methylsulfonyl) phenyl] -5-(trifluoromethyl)-lH-pyrazole ; Compound Structural Formula Number o=s=o F B-159 N A F F 5- (4-fluorophenyl)-4- (4-methylsulfonylphenyl) - 2-trifluoromethyl-lH-imidazole ; o=s=o u-S=--O B-160 N NH F F F F 4- [4- (methylsulfonyl) phenyl]-5- (2-thiophenyl)-2- (trifluoromethyl)-lH-imidazole ; Compound Structural Formula Number F F F F N B-161 , o 0 5- (4-fluorophenyl)-2-methoxy-4- [4- (methylsulfonyl) phenyl]-6- (trifluoromethyl) pyridine ; F F F N B-162 0 o s 2-ethoxy-5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl] -6-(trifluoromethyl) pyridine ; 0 SX /°Xv B-163 F F I/ F F 5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl] -2-(2-propynyloxy)-6-(trifluoromethyl) pyridine ; Compound Structural Formula Number F F /\F Br F B-164 zu o 2-bromo-5- (4-fluorophenyl)-4- [4- (methylsulfonyl) phenyl] -6-(trifluoromethyl) pyridine ; F F B-165/ cri cri 4-[2-(3-chloro-4-methoxyphenyl)-4, 5-difluorophenyl] benzenesulfonarnide ; Compound Structural Formula Number o=s=o \ F B-165 I 1- (4-fluorophenyl)-2- [4-methylsulfonyl) phenyl] benzene ; F A-0 ZOZO zon B-167 o zon 5-difluoromethyl-4- (4-methylsulfonylphenyl)-3-phenylisoxazole ; 0 N B-168 B-168 0 N H 2 0 4- [3-ethyl-5-phenylisoxazol-4-yl] benzenesulfonamide ; Compound Structural Formula Number F Zozo ZOZO zon B-169 X zozo NHZ o 4- [5-difluoromethyl-3-phenylisoxazol-4-yl] benzenesulfonamide ; OH O\ \nu B-170 0 . OH 4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide ; 0 Zon B-171 0 Nu NH 4- [5-methyl-3-phenyl-isoxazol-4-yl] benzenesulfonamide ; Compound Structural Formula Number /% ° n B-172 F 1- [2- (4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; °% s/ /0 B-173 F 1- [2- (4-fluoro-2-methylphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; B-174 Ci B-174 ci 1- [2- (4-chlorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; Compound Structural Formula Number zu se cri ci 1-[2-(2, 4-dichlorophenyl) cyclopenten-1-yl]-4-(methylsulfonyl) benzene ; 0 /o B-176 F /F 1- [2- (4-trifloromethylphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; ' ? S\O B-177 \ S 1- [2- (4-methylthiophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; Compound Structural Formula Number zu s B-178 F 1- [2- (4-fluorophenyl)-4, 4-dimethylcyclopenten-1-yl] 4- (methylsulfonyl) benzene ; 0 \ 1 B-179 F 4- [2- (4-fluorophenyl)-4, 4-dimethylcyclopenten-1-yl] benzenesulfonamide ; 0 B-180 Cil o 1- [2- (3-chlorophenyl)-4, 4-dimethylcyclopenten-1-yl]-4- (methylsulfonyl) benzene ; Compound Structural Formula Number o nu2 B-181 Cil 4- [2- (4-chlorophenyl)-4, 4-dimethylcyclopenten-1-yljbenzenesulfonamide ; NH2 0 B-182 F 4- [2- (4-fluorophenyl) cyclopenten-1-yl] benzenesulfonamide ; NH2 po B-183 Bs ci 4- [2- (4-chlorophenyl) cyclopenten-1-yl] benzenesulfonamide ; Compound Structural Formula Number °\\s/ So B-184 0 1- [2- (4-methoxyphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; \ F O B-185 \/ zu F/ 1- [2- (2, 3-difluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; N dz Po 0 0 o 4- [2- (3-fluoro-4-methoxyphenyl) cyclopenten-1-yl] benzenesulfonamide ; Compound Structural Formula Number 7 ,-/° B-187 cl o 1- [2- (3-chloro-4-methoxyphenyl) cyclopenten-1-yl]-4- (methylsulfonyl) benzene ; NHZ po B-188 cl F F 4- [2- (3-chloro-4-fluorophenyl) cyclopenten-1-yl] benzenesulfonamide ; NH /0 B-189 N 4- [2- (2-methylpyridin-5-yl) cyclopenten-1-yl] benzenesulfonamide ; Compound Structural Formula Number jA/ 0 0 N B-190 vot po / ethyl 2- [4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazol-2-yl]-2-benzyl-acetate ; po 0\ O B-191 zozo f/ N OH F 2- [4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] acetic acid ; F N N B-192 I 0 o 2- (tert-butyl)-4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl] oxazole ; Compound Structural Formula Number zu o s B-193 0 \ \N \ F 4- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl]-2-phenyloxazole ; F / N B-194 % JS /sV o 4- (4-fluorophenyl)-2-methyl-5- [4- (methylsulfonyl) phenyl] oxazole ; Compound Compound Structural Formula Number F F F F L F Po \ F B-19 \5 \/ NHz 4- [5- (3-fluoro-4-methoxyphenyl)-2-trifluoromethyl - 4-oxazolyl] benzenesulfonamide ; 0 ce oN F B-196/ F F F 6-chloro-7- (1, 1-dimethylethyl)-2-trifluoromethyl-2H - 1-benzopyran-3-carboxylic acid ; o ci zou B-197 F / po 0 F 6-chloro-8-methyl-2-trifluoromethyl-2H-l-benzopyran-3-carbox ylic acid ; Compound Structural Formula Number ou B-198 0 s 0 5, 5-dimethyl-3- (3-fluorophenyl)-4-methylsulfonyl-2 (5H)-furanone ; 0 ce OU I F B-199 s F F 6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid ; F F F FEZ N\ B-200 cri zu vs NHZ O 4- [5- (4-chlorophenyl)-3- (trifluoromethyl)-lH-pyrazol-1-yl] benzenesulfonamide ; Compound Structural Formula Number F F F NEZ N\ B-201 \\S\\ NH2/% 0 4-ES-(4-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-l-yl] benzenesulfonamide ; F F ZON B-202 /o / F S\ /0'NHz /O 4- [5- (3-fluoro-4-methoxyphenyl)-3- (difluoromethyl) -IH-pyrazol-1-yl] benzenesulfonamide ; zon 0 O zu 11 l 0 F F 3- [l- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl-lH-imidazol-2-yl] pyridine ; Compound Structural Formula Number F F IF N \\ N B-204 zon S 2-methyl-5- [1- [4- (methylsulfonyl) phenyl]-4-trifluoromethyl - 1 H-imidazol-2-yl] pyridine ; N zon N B-205 NHzSH (N F if F 4- [2- (5-methylpyridin-3-yl)-4- (trifluoromethyl) - 1 H-imidazol-1-yl] benzenesulfonamide ; 0 0 B-206 ° s NHZ O N 4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide ; Compound Structural Formula Number OH 0 0 Nu2 \O \ 4- [5-hydroxymethyl-3-phenylisoxazol-4-yl] benzenesulfonamide ; F F 0 F B-208 NH F F O=S=O [2-trifluoromethyl-5- (3, 4-difluorophenyl)-4-oxazolyl] benzenesulfonamide ; NH2 0 Zu B-209 /y-° Cyk 4- [2-methyl-4-phenyl-5-oxazolyl] benzenesulfonamide ; 4- [2-meiyl-4-phenyl-5-oxazolyl] benzenesulionanude ; Compound Structural Formula Number F F F F F N ///N O B-210 I i o=S=o NH NHz 4- [5- (2-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl] benzenesulfonamide ; Q CHz Ct B-211 I NH H3C F 0 S-CH3 NH-11"11 0 0 B-212 NOz N-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide or Nimesulide Compound Structural Formula Number F F 0 B-213 B-213 NEZ I o=s=o N-[6-(2, 4-difluoro-phenoxy)-1-oxo-inden-5-yl]-methanesulfonamide or Flosulide F F 0 s B-214 Nua _N O=S=O IV-[6-(2, 4-difluoro-phenylsulfanyl)-1-oxo-lH-inden-5-yl]-methanesulfo namide, soldium salt, or L-745337 F \ S o B-Z1S p NH S/\S N- [5- (4-fluoro-phenylsulfanyl)-thiophen-2-yl]-methanesulfonamide or RWJ-63556 Compound Structural Formula Number F F 0 0 \ F F PO B-216 / po 3- (3, 4-difluoro-phenoxy)-4- (4-methanesulfonyl-phenyl)-5-methyl - 5- (2, 2, 2-trifluoro-ethyl)-5H-furan-2-one or L-784512 zu N NHZ B-217 'OH OH (5Z)-2-amino-5- [ [3, 5-bis (l, 1-dimethylethyl)-4-hydroxyphenyl] methylene] -4 (5H)-thiazolone or Darbufelone B-218 CS-502 B-219 LAS-34475 B-220 LAS-34555 Compound Structural Formula Number B-221 S-33516 B-222 SD-8381 B-223 L-783003 nu NU 0 po O B-224 s T) 00/< c 1 J B-224 " N H 0 N- [3- (formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] -methanesulfonamide or T614 B-225 D-1367 B-226 L-748731 Compound Compound Structural Formula Number H \O HO B-227 o/ Ha (6aR, 1 OaR)-3-(1, 1-dimethylheptyl)-6a, 7, 10, 1 Oa-tetrahydro-l-hydroxy-6, 6-dimethy 1-6H-dibenzo [b, d] pyran-9-carboxylic acid or CT3 B-228 CGP-28238 HO \O B-229 \/I \ \ 0 4- [ [3, 5-bis (l, 1-dimethylethyl)-4-hydroxyphenyl] methylene] dihydro-2-methyl-2H-1, 2-oxazin-3 (4H)-one or BF-389 B-230 GR-253035 HO 0 B-231 NH N O 2-(6-dioxo-9H-purin-8-yl) cinnamic acid Compound Structural Formula Number B-232 S-2474 0 \OH Cl H B-233 tAwN\ » \ cl H H

The cyclooxygenase-2 selective inhibitor employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. Generally speaking, suitable cyclooxygenase-2 selective inhibitors that are in tautomeric, geometric or stereoisomeric forms are those compounds that inhibit cyclooxygenase-2 activity by about 25%, more typically by about 50%, and even more typically, by about 75% or more when present at a concentration of 100 je, M or less. The present invention contemplates all such compounds, including cis-and trans-geometric isomers, E-and Z-geometric isomers, R- and S-enantiomers, diastereomers, d-isomers, 1-isomers, the racemic mixtures thereof and other mixtures thereof. Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention. The terms "cis"and"trans", as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond ("cis") or on opposite sides of the double bond ("trans"). Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or"E"and"Z"geometric forms. Furthermore, some of the compounds described contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

The cyclooxygenase-2 selective inhibitors utilized in the present invention may be in the form of free bases or pharmaceutically acceptable acid addition salts thereof.

The term"pharmaceutically-acceptable salts"are salts commonly used to form alkali

metal salts and to form addition salts of free acids or free bases. The nature of the salt may vary, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of compounds for use in the present methods may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable phannaceutically-acceptable base addition salts of compounds of use in the present methods include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of any Formula set forth herein.

The cyclooxygenase-2 selective inhibitors useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co. , Easton, Pennsylvania

(1975), and Liberman, H. A. and Lachman, L. , Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N. Y. (1980).

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the cyclooxygenase-2 selective inhibitor will vary depending upon the patient and the particular mode of administration. In general, the pharmaceutical compositions may contain a cyclooxygenase-2 selective inhibitor in the range of about 0.1 to 2000 mg, more typically, in the range of about 0.5 to 500 mg and still more typically, between about 1 and 200 mg. A daily dose of about 0.01 to 100 mg/kg body weight, or more typically, between about 0.1 and about 50 mg/kg body weight and even more typically, from about 1 to 20 mg/kg body weight, may be appropriate. The daily dose can be administered in one to about four doses per day.

In one embodiment, when the cyclooxygenase-2 selective inhibitor comprises rofecoxib, it is typical that the amount used is within a range of from about 0.15 to about 1.0 mg/day-kg, and even more typically, from about 0.18 to about 0.4 mg/day kg.

In still another embodiment, when the cyclooxygenase-2 selective inhibitor comprises etoricoxib, it is typical that the amount used is within a range of from about 0.5 to about 5 mg/day-kg, and even more typically, from about 0.8 to about 4 mg/day-kg.

Further, when the cyclooxygenase-2 selective inhibitor comprises celecoxib, it is typical that the amount used is within a range of from about 1 to about 20 mg/day-kg, even more typically, from about 1.4 to about 8.6 mg/day kg, and yet more typically, from about 2 to about 3 mg/day. kg.

When the cyclooxygenase-2 selective inhibitor comprises valdecoxib, it is typical that the amount used is within a range of from about 0.1 to about 5 mg/day kg, and even more typically, from about 0.8 to about 4 mg/day kg.

In a further embodiment, when the cyclooxygenase-2 selective inhibitor comprises parecoxib, it is typical that the amount used is within a range of from about 0.1 to about 5 mg/day-kg, and even more typically, from about 1 to about 3 mg/day kg.

Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711 and from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Tenth Edition (2001), Appendix I, pp. 475-493.

Carbonic Ankydrase Inhibitors A number of suitable carbonic anhydrase inhibitors or pharmaceutically acceptable salts or prodrugs thereof may be employed in the method of the present invention. Typically, the carbonic anhydrase inhibitor employed does not inhibit cyclooxygenase-2. In one embodiment, the carbonic anhydrase inhibitor can be, for example, methazolamide, Formula A-1 (CAS registry number 554-57-4) or a pharmaceutically acceptable salt or prodrug thereof.

In another embodiment, the carbonic anhydrase inhibitor can be, for example, acetazolamide, Formula A-2 (CAS registry number 59-66-5) or pharmaceutically acceptable salt or prodrug thereof.

In yet another embodiment, the carbonic anhydrase inhibitor can be, for example, dichlorphenamide Formula A-3 (CAS registry number 120-97-8) or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the carbonic anhydrase inhibitor is selected from the group consisting of benzothiazole sulfonamides having the general Formula I shown below and possessing, by way of example and not limitation, the structures disclosed in Table 1.

Furthermore, benzothiazole sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 4,975, 449 and 5,059, 613, both of which are herein incorporated by reference in their entirety.

wherein: each Ri is hydrogen, lower alkyl, halogen, nitro, trihaloalkyl, lower alkoxy, formyl, lower alkanoyl loweralkylamino or diloweralkylamino; R6 is hydrogen or lower alkyl ; Y, is :

wherein: Xl is O or NRS or S ; R2 is OR7 or NR7 R8 ; each R3 and R4 are hydrogen or lower alkyl ; R5, R7 and Rg are independently hydrogen or lower alkyl ; m is an integer which is 0,1, 2,3, 4,5, or 6, and n is an integer which is 0,1, 2, or 3.

TABLE 1 Compound No. Compound A-4 6-hydroxy-2-benzothiazole sulfonamide A-5 6- (ethyloxalyloxy)-2-benzothiazole sulfonamide A-6 6- (ethylsuccinyloxy)-2-benzothiazole sulfonamide A-7 nez O O O --S02NH2 o CH3CH2OC-C-N H A-8 N\\ A-8 0-S02NH2 CH3CH20C- (CH2) 2CN S 11 H 0

In another embodiment, the carbonic anhydrase inhibitor is selected from the class of benzothiazolesulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula IIa shown below and possessing, by way of example and not limitation, the structures disclosed in Table 2a. Furthermore, benzothiazolesulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,095, 026 and 5,157, 044, both of which are herein incorporated by reference in their entirety. wherein: Zl represents a water soluble carrier, and Al is a moiety which is attached to the carbonic anhydrase inhibitor which allows it to still retain carbonic anhydrase inhibitory activity, but also form an enzymatically cleavable bond between Al and Zl.

TABLE 2A Compound No. Compound A-9 N-methyl-2-benzothiazolesulfonamide A-10 N-acetyl-2-benzothiazole-sulfonamide A-11 N-acetyl-6-ethoxy-2-benzothiazolesulfonamide A-12 6-ethoxy-N-methyl-2-benzothiazolesulfonamide A-13 6-ethoxy-N-propyl-2-benzothiazolesulfonamide A-14 6-hydroxy-N-methyl-2-benzothiazolesulfonamide A-15 6-hydroxy-2-benzothiazole-sulfonamide A-16 6-chloro-2-benzothiazolesulfonamide A-17 6-0-acetyl-2-acetyl-2-benzothiazolesulfonamide A-18 6-hydroxyethoxybenzothiazolesulfonamide A-19 6-benzyloxybenzothiazole-2-sulfonamide A-20 7-chloro-2-benzothiazolesulfonamide A-21 6 amino-benzothiazolesulfonamide A-22 6-fluoro-2-benzothiazolesulfonamide A-23 6-bromo-2-benzothiazolesulfonamide A-24 4, 6-dichloro-2-benzothiazolesulfonamide

In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of hydroxymethazolamide carbonic anhydrase inhibitors represented by the general structure of Formula IIb shown below and possessing, by way of example and not limitation, the structures disclosed in Table 2b. Furthermore, hydroxymethazolamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,095, 026 and 5,157, 044, both of which are herein incorporated by reference in their entirety. wherein: Z2 represents a water soluble carrier, N is 1,2, 3,4, or 5 ; and A2 is a moiety which is attached to the carbonic anhydrase inhibitor which allows it to still retain carbonic anhydrase inhibitory activity, but also form an enzymatically cleavable bond between A2 and Z2.

TABLE 2B Compound No. Compound A-25Hydroxymethazolamide A-26 N- [5- (aminosulfonyl)-3-methyl-1, 3, 4-triadiazol-2 (3H) - ylidene] hydroxyacetamide A-27 Hydroxyethoxymethazolamide A-28 N- [5- (aminosulfonyl)-3-methyl-1, 3,4-triadiazol-2 (3H) - ylidene] hydroxyethoxyacetamide A-29 N- [5- (aminosulfonyl)-3-methyl-1, 3,4-thiazol-2 (3H)-ylidene]-2- [glycolylhydroxy] acetamide

In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of dichlorophenamide carbonic anhydrase inhibitors represented by the general structure of Formula IIc shown below and possessing, by way of example and not limitation, the structures disclosed in Table 2c. Furthermore, dichlorophenamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S.

Patent No. 5,095, 026 and 5,157, 044, both of which are herein incorporated by reference in their entirety.

wherein: Z3 represents a water soluble carrier; and A3 is a moiety which is attached to the carbonic anhydrase inhibitor which allows it to still retain carbonic anhydrase inhibitory activity, but also form an enzymatically cleavable bond between A3 and Z3.

TABLE 2C Compound No. Compound A-30 4-hydroxy-5-chloro-m-benzenedisulfonamide A-31 4-hydroxyethoxy-5-chloro-m-benzenedisulfonamide A-32 4-hydroxyacetamido-5-chloro-M-benzenedisulfonamide A-33 4-hydroxyethoxyacetamido-5-chloro-m-benzenedisulfonamide A-34 4-amino-6-chloro-m-benzenedisulfonamides A-35 4-hydroxyacetamido-6-chloro-m-benzenedisulfonainides A-36 4-hydroxy-6-chloro-M-benzenedisulfonamides A-37 4-hydroxyethoxy-6-chloro-m-benzenedisulfonamides A-38 4-chloro-5-hydroxy-m-benzenedisulfonamides A-39 4-chloro-5-hydroxyethoxy-m-benzenedisulfonamides A-40 4-amino-5-chloro-m-benzenedisulfonamides A-41 4-chloro-5-amino-m-benzenedisulfonamides A-42 4-chloro-5-hydroxyacemido-m-benzenedisulfonamides

In still another embodiment, the carbonic anhydrase inhibitor is selected from the class of methazolamide carbonic anhydrase inhibitors represented by the general structure of Formula III shown below and possessing, by way of example and not limitation, the structures disclosed in Table 3. Furthermore, methazolamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S.

Patent No. 5,104, 887, both of which are herein incorporated by reference in their entirety.

wherein: n is an integer which is 0,1, 2,3, 4, or 5; X2 is hydrogen, hydroxyl, hydroxylmethyl, 2-hydroxyethyl, or 2- hydroyethoxy ; Arl is phenyl, pyridyl, or furanyl; and in is an integer which is 0,1, 2,3, or 4.

TABLE 3 Compound No. Compound A-43 6- [1-glucopyranosyl) oxyethoxy]-2-benzothiazolesulfonamide A-44 2-ethoxycarbonylimino-3-methyl-delt4-1, 3, 4-thiadiazoline-5- sulfonamide A-45 3-methyl-delta4-1, 3, 4-thiadiazoline-5-sulfonamide A-46 2- [4-pyridylmethyloxycarbony] imino-3-methyl-delta-1, 3,4- thiadiazoline-5-sulfonamide A-47 2-[4-hydroxymethylbenzyloxycarbonyl]imino-3-methyl-delta4- 1,3, 4-thiadiazoline-5-sulfonamide A-49 2-L4-hydroxymethylphenylacetyl] imino-3-methyl-delta-1, 3,4- thiadiazoline-5-sulfonamide A-50 2-benzyloxcarbonylimino-3-methyl-delta4-1, 3, 4-thiadiazoline- 5-sulfonamide A-51 2-ethoxycarbonylimino-3-methyl-delta4-1, 3, 4-thiadiazoline-5- sulfonamide

In another embodiment, the carbonic anhydrase inhibitor is selected from the class of thiophene sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula IV shown below and possessing, by way of example and not limitation, the structures disclosed in Table 4. Furthermore, thiophene sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,153, 192,5, 240,923, 5,378, 703, and 5,620, 970, all of which are herein incorporated by reference in their entirety.

wherein: R9 is H, Cl4 alkyl, C2-4 alkyl substituted optionally with OH, halogen, C14 alkoxy, or C (=O) R15 ; Rio is H; C1-8 alkyl ; C2 s alkyl substituted with OH, NR13R14, halogen, C1 4 alkoxy or C (=O) RI5 ; C3-7 alkenyl unsubstituted or substituted optionally with OH, NRi3Rm, or C1-4 alkoxy ; C3-7 alkynyl unsubstituted or substituted optionally with OH, NRz3Rl4, or Ci- 4 alkoxy, Cl 3 alkyl substituted with phenyl or heteroaryl which can be unsubstituted or substituted optionally with OH, (CH2)nNR13R14, halogen, C1-4 alkoxy, C1-4 haloalkoxy,

C (=O) Ris, S (=O) R16 or SO2NR13R14, wherein m is 0-2 and n is 0-2; C2-4 alkoxy substituted optionally with NR13R14, halogen, C1-4 alkoxy, or C (=O) RIS ; phenyl, or heteroaryl, unsubstituted or substituted optionally with OH, (CH2)n NR13R14, halogen, C1-4 alkoxy, C1-4 haloalkoxy, C (=O) Rls, S (=O) m R16 or S02 NRi3Rm, wherein m is 0-2 and n is 0-2; provided that Rg and Rio cannot both be H; or Rg and Rio can be joined to form a saturated ring of 5 or 6 atoms selected from O, S, C or N which can be unsubstituted or substituted optionally on carbon with OH, NR13R14, halogen, C14 alkoxy, C (=O) R15, C1-6 alkyl, C1-6 alkyl substituted optionally with OH, NR13RI4, halogen, C14 alkoxy, C (=O) RI5 or on nitrogen with NR13R14, C1g alkoxy, C (=O) R15, C i- 6 alkyl or C2-6 alkyl substituted optionally with OH, NR13R14, halogen, Cul-4 alkoxy or C (=O) Ri ; Rll is H; halogen; C1-4 alkyl ; C1-8 alkoxy; C1-8 alkylthiol; C2-8 alkoxy substituted optionally with OH, NR13RI4, halogen, C1-4 alkoxy or C (=O) R15 ; C 1-4 alkyl substituted optionally with R12 ; or Rg and Rll can be joined together with carbon atoms to form a ring of from 5 to 7 members in which said carbon atoms can be unsubstituted or substituted optionally with R12 ; R12 is OH; C1-4 alkyl unsubstituted or substituted optionally with OH, NR13R14, halogen, Cri-4 alkoxy or C (=O) RI5 ; Ci-4 alkoxy; C2-4 alkoxy substituted optionally with OH, NR13R14, halogen, C1-4 alkoxy or C (=O) Ri5 ; NR13RI4 ; phenyl, or heteroaryl, unsubstituted or substituted optionally with OH, (CH2)n NR13R14, halogen, C1-4 alkoxy, C1-4 haloalkoxy, C (=O) Rls, S (=O) m R16 or SO2NR13R14, wherein m is 0-2 and n is 0-2; R13 and R14 are the same or different and are H; C1-4 alkyl ; C2-4 alkyl substituted optionally with OH, halogen, C1-4 alkoxy or C (=O) Ris ; ; C1-4 alkoxy; C24 alkoxy substituted optionally with OH, halogen, C14 alkoxy or C (=O) Ris ; C3-7 alkenyl unsubstituted or substituted optionally with OH, NR13RI4, or C14 alkoxy; C3-7 alkynyl unsubstituted or substituted optionally with OH, NR13R14, or C14 alkoxy; C1-2 alkylC3-5 cycloalkyl ; or R13 and R14 can be joined to form a ring of 5 or 6 atoms selected from O, S, C or N which can be unsubstituted or substituted optionally on carbon with OH, (=O), halogen, Cri-4 alkoxy, C (=O) Ri5, C1-6 alkyl, C1-6 alkyl substituted optionally with OH, halogen, Cl alkoxy, C (=O) Ri5 or on nitrogen with Cl alkoxy, C (=O) R15, S (=O). mRl6 Cl 6 alkyl or C26 alkyl substituted optionally with OH, halogen, C1-4 alkoxy, C (=O) RI5 or on sulfur by (=O) m, wherein m is 0-2;

R15 is Cl-s alkyl ; C1-8 alkyl substituted optionally with OH, NR13R14, halogen, C1-4 alkoxy or C (=O) Ri7 ; Ci-4 alkoxy; C2-4 alkoxy substituted optionally with OH, NR13R14, halogen or C14 alkoxy; or NR13RI4 ; R16 is C1-4 alkyl ; C24 alkyl substituted optionally with OH, NR13R14, halogen, C1-4 alkoxy or C (=O) R15 ; and R17 is C1-4 alkyl; C1-4 alkoxy; amino, C1-3 alkylamino, or di-C1-3 alkylamino; and G1 is C (=O) or SO2. TABLE 4 Compound No. Compound A-52 H \ I -SOzNHz N/S S N- [2- (4-morpholinyl) ethyl]-2, 5-thiophenedisulfonamide hydrochloride A-53"'NH \S02NH2 CH3 NS S ou HCI 0 HC ! 4-ethylamino-3, 4-dihydro-2-methyl-2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1 dioxide hydrochloride A-54 CH3O N -SOzNHz Nw S S 02 HCI 5-[[4-(2-methoxyethyl) piperazinyl] sulfonyll-2- thiophenesulfonamide hydrochloride A-55 HO N-S02NH2 s"f S> N S S 02 HCI 5-[[4-12-hydroxyethyl) piperazinyl] sulfonyl]-2- thiophenesulfonamide hydrochloride TABLE 4 Compound No. Compound A-56 A-56 Et S02NH2 N HUI O hui O 2 N-ethyl-N- [2- (4-morpholinyl) ethyl]-2, 5- thiophenedisulfonamide hydrochloride A-57 NU "'T' I NHz CH3 S S HCt 02 3, 4-dihydro-2-methyl-4- (2-methyl) propylamino-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-58 OH \S02NH2 N s s HCI 02 01 3, 4-dihydro-4-hydroxy-2-12- {4-morpholinyl) ethyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-59 B H -SOsNHs S02NH2 s 02 HCI oi 4-bromo-5- [ [2- (4-morpholinyl) ethyl] amino] sulfonyl-2- thiophenesulfonamide hydrochloride A-60 HO Br N Lu su Nazis 02 HO p2 HCI 4-bromo-5-[[4-(2-hydroxyethyl)-piperazinyl] sulfonyl]-2- thiphenesulfonamide hydrochloride TABLE 4 Compound No. Compound A-61/\NH nu-NHz CL 3 HCI 02 R- (+)-4-ethylamino-3, 4-dihydro-2-methyl-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-62/\NH NC-S02NH2 CL 3 HUI 02 R- (+)-4-ethylamino-3, 4-dihydro-2-methyl-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-63 NH I S02NH2 N S S HCI 02 2-allyl-4-ethylamino-3, 4-dihydro-2H-thieno [3, 2-e]-1, 2-thiazine- 6-sulfonamlde 1, 1-dioxide hydrochloride A-64 nu -SOzNHz N - CH30 S S HCI 02 02 3, 4-dihydro-2- (2-methoxy) ethyl-4-propylamino-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-65/\NH S02NH2 N CH3 s HCI 02 4-ethylamino-3, 4-dihydro-2- (2-methoxy) ethyl-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-66 S02NH2 N EtO-'s HCI 02 02 2- (2-ethoxy) ethyl-4-ethylamino-3, 4-dihydro-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-67 N H-R N S02NH2 N R2 OO S HCI A-68 UNI f f -SOsNHz \S02NH2 N 02 02 R- (+)-3, 4-dihydro-2- (2-methoxy) ethyl-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-69/\N H \-SONH N CH30, S HCI 02 R- (+)-4-ethylamino-3, 4-dihydro-2- (2-methoxy) ethyl-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-70 NH NU 46,'tg 2 HUI 02 O2 TABLE 4 Compound No. Compound A-71-""NH N I S02NH2 S HUI 02 4-ethylamino-3, 4-dihydro-2- (4-pyridinyl) methyl-2H-thieno 3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-72 COSH CC02H OH C02NH2 N N s HCI H3CacNJ 0 2- [1- (4-acetyl-piperazinyl)] ethyl-3, 4-dihydro-4-hydroxy-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide- 1, 1-dioxide maleate A-73 HCI OH S02NH2 N OUZO OU 3, 4-dihydro-hydroxy-2- [2- (N, N-dimethoxyethyl) aminoethyl]- 2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-74 HCI OH N NHz 0--"0 S NEZ 3, 4-dihydro-4-hydroxy-2, 2-imidazol-1-yl) ethyl-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-75 HCl HsC'NH \S02NH2 Nez N./o0 S N 4-ethylamino-3, 4-dihydro-2-2- (4-morpholinyl) ethyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-76 HCI HN CHs H3C s S02NH2 0 . N / O O " 00 (-)-4-ethylamino-3, 4-dihyro-2- (3-methoxy) propyl-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-77 HCI HN<CH3 HUI S02NH2 S HsC 0 O O (+)-2- (2-ethoxy) ethyl-4-ethylamino-3, 4-dihydro-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-78 HCI HN<CH3 I/4 S°2NH2 LJ r \) JL/ H3C0/N S ouzo "oo 4-ethylamino-3, 4-dihydro-2-trans- (4-methoxy)-2-butenyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-l, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-79 HCI HNCH3 -SOzNHz On H3C OO S 4-ethylamino-3, 4-dihydro-2- [cis- (4-methoxy)-2-butenyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-80 HCI HN CH3 S02NH2 N Ouzo oo 4-ethylamino-3, 4-dihydro-2- (3-hydroxy) propyl-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-81 HCI HN <CH3 N S02NH2 Q " oo 4-ethylamino-3, 4-dihydro-2- (2-hydroxy) ethyl-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-82 H3C 0 S02NH2 N zozo 2, 3-dihydro-3-methyl-2-[2-(4-morpholinyl) ethyll-thienol3, 2- d]-isothiazole-5-sulfonamide-1, 1-dioxide A-83 HN-Et HC) \S02NH2 H3CO (CH2) 3Ns zS O"somo (+)-4-ethylamino-3, 4-dihydro-2- (3-methoxy) propyl-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-84 \- ! !)-S02NH2 H3CO- (CH2) 3- s S02NH2 OUZO 3, 4-dihydro-2- (3-methoxypropyl)-2H-thieno [3, 2-e]-1, 2- thiazine-6-sulfonamide-1, 1-dioxide sodium salt A-85 HCI HN, CH2CH3 HN hic N NHz ouzo 4-ethylamino-3, 4-dihydro-2- (4-methylphenyl) methyl-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-86 HCI CH2CH3 N N2 I \ OO S Ho Ho 4-ethylamino-3, 4-dihydro-2- [4- (2-hydroxyphenyl) phenyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dixoide hydrochloride A-87 HCI CH2CH2CH3 HN" f) -S02NH2 nez J oo R- (+)-3, 4-dihydro-2- (2-phenylethyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-88 H3C \S02NH2 H3CO- (CH2) 3Ns Jl Se OUZO s 3, 4-dihydro-2- (3-methoxypropyl)-3-methyl-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-89 HCI HN, CH2CH2CH3 HN f ! -SOzNHz H3CO- (CH2) 4 N S OUZO R- (+)-3, 4-dihydro-2- (4-methoxybutyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-90 HCt. CHsCHg HN f f--SOzNHs H3CO- (CH2) 4 No$) S OUZO R- (+)-4-ethylamino-3, 4-dihydro-2- (4-methoxybutyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-91 HCI HAN" S09NH,, F- (CH2) 3-N OUZO 4-ethylamino-2- (3-fluoropropyl) 3, 4-dihydro-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 4 Compound No. Compound A-92 han HN rr t -SOzNHz H3CO- (CH2) 3-nez ozons R- (-)-4-ethoxy-3, 4-dihydro-2- (3-methoxypropyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-93 HCI HX CH3 \>--S02NH2 NU 0 6-ethyl-4-ethylamino-4, 5, 6, 7-tetrahydro-7-oxo-thieno [2, 3- b] pyridine-2-sulfonamide hydrochloride A-94 HCI HIN CH3 N, \ S02NH2 0 O 4-ethylamino-4, 5, 6, 7-tetrahydro-7-oxo-6- (phenylmethyl)- thieno [2, 3-b] pyridine-2-sulfonamide hydrochloride A-95 H N-_ S NH N- (2-thienyl) methyl-2, 5-thiophenedisulfonamide A-96 H N N-(phenylmethyl)-5-(aminosulfonyl)-thiophene-2-carboxamide In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of methazolamide carbonic anhydrase inhibitors represented by the general

structure of Formula V shown below and possessing, by way of example and not limitation, the structures disclosed in Table 5. Furthermore, methazolamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S.

Patent No. 5,225, 424, which is herein incorporated by reference in its entirety.

In one embodiment, Ri is Ci-a. In another embodiment, Rl7 is Cl. In still another embodiment, R17 is methyl. TABLE 5 Compound No. Compound A-97 N- [5- (aminosulfonyl)-3-methyl]-1, 3, 4-thiadiazol-2 (3H)- ylidene]-2-acetyloxyacetamide A-98 H3C\ o O NN ! t tt H3C-COCH2 llNX) S S02NH2 N- [5- (aminosulfonyl)-3-methyl]-1, 3, 4-thiadiazol-2 (3H)- ylidene]-2-acetyloxyacetamide

In still another embodiment, the carbonic anhydrase inhibitor is selected from the class of thienothiazine sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula VI shown below and possessing, by way of example and not limitation, the structures disclosed in Table 6. Furthermore, thienothiazine sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,344, 929 and 5,424, 448, both of which are herein incorporated by reference in their entirety.

wherein: Ris and Rig are H or C1-4 alkyl ; R20 is C1-6 alkyl, CH2 (CH2) nOR21, where n is 1-4 ; and R21 is CH3, (CH2) nCH3 where n is 1-4, or (CH2) nAr2 where Ar2 is unsubstituted phenyl, 3-methoxyphenyl, or 4-methoxyphenyl and n isl or 2. TABLE 6 Compound No. Compound A-99 OH cl 1H 02 (S)-3, 4-dihydro-6-chloro-4-hydroxy-2H-thieno [3, 2-e]-1, 2- thiazine-1, 1-dioxide A-100 NHCH2CH3 CL H2NO2S N ""OCH3 02 (R)-3, 4-dihydro-4-ethylamino-2- (2-methoxyethyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide hydrochloride A-101 NHCH2CH3 HCI Hui 2NOUS 4 OCH3 N OCH3 02 (R)-3, 4-dihydro-4-ethylamino-2- (3-methoxypropyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide A-102 NHCH2CH2CH3 H2NO2S s 02 (R)-3, 4-dihydro-2- (4-methoxybutyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide A-103 0 CI A-104 0 Br ci s S02NH2

In a further embodiment, the carbonic anhydrase inhibitor is selected from the class of thienothiazine sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula VII shown below and possessing, by way of example and not limitation, the structures disclosed in Table 7. Furthermore, thienothiazine sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,464, 831, which is herein incorporated by reference in its entirety.

wherein: R22 is H, C1-6 alkyl unsubstituted or substituted optionally with OH, Cl alkoxy, NR24R25, OC (=O) R26 or C (=O) R26 ; R23 is H; C1-8 alkyl ; C1-8 alkyl substituted with OH, NR24R25, halogen, Cl alkoxy, C2-4 alkoxy, Cl alkoxy, OC (=O) R26, S (=O) m R28, or C (=O) R26 ; C3-7 alkenyl unsubstituted or substituted optionally with OH, NR24R25, or Cl4 alkoxy; C3-7 alkynyl unsubstituted or substituted optionally with OH, NR2RR25, or Cl alkoxy ; C0-3 alkyl substituted with R27 which can be unsubstituted or substituted optionally with C1-3 alkyl, C1-3 ahloalkyl, OH, (CH2)n NR24R25, halogen, Cl alkoxy, CI-4 haloalkoxy, OC (=O) R26, C (=O) R26, S (=O)m R28 or SO2 NR24R25, wherein m is 0-2 and n is 0-2; R24 and R25 are independently H; C1-8 alkyl ; C2-4 alkyl substituted optionally with OH, halogen, C1-4 alkoxy or C (=O) R26; OH; C1-4 alkoxy; C2-4 alkoxy substituted optionally with OH, halogen, Ci-4 alkoxy or C (=O) R26; or R24 and R25 can be joined to form a ring of 5 or 6 atoms selected from O, S, C or N which can be unsubstituted or substituted optionally on carbon with OH, (=O), halogen, C1-4 alkoxy, C (=O) R26, Cl 6 alkyl, C1-6 alkyl substituted optionally with OH, halogen, Cl4 alkoxy, C (=O) R26 or on nitrogen with Cl4 alkoxy, C (=O) R26, S (=O) m R28, C1-6 alkyl or C2-6 alkyl substituted optionally with OH, halogen, C1-4 alkoxy, C (=O) R26 or on sulfur by (=O) m, where m is 0- 2; R26 is Cl 8 alkyl ; C1-4 alkyl substituted optionally with OH, NR24R25, halogen, C1-4 alkoxy or C (=O) R29 ; Cl4 alkoxy; C2-4 alkoxy substituted optionally with OH, NR24R25, halogen or C1-4 alkoxy; or NR24R25; R27, is a monocyclic ring system of 5 or 6 atoms composed of C, N, O or S, such as benzene, furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, isothiazole, thiazole, thiadiazole, pyridine pyrimidine, pyridazine, and pyrazine; R28 is Cl alkyl ; C2-4 alkyl substituted optionally with OH, NR24R25, Cl4 alkoxy or C (=O) R26; R27 which can be unsubstituted or substituted optionally with OH, (CH2)n NR24R25, halogen, C1-4 alkoxy, C1-4 haloalkoxy, C (=O) R26, S (=O) m C14 alkyl or SO2 NR24R25 ; wherein m is 0-2 and n is 0-2 ; and R29 is Cl 4 alkyl ; C1-4 alkoxy ; amino, C1-3 alkylamino, of di-C1-3 alkylamino. "TABLE 7 compound No. Compound A-105 S02NH2 N OUZO 2- (2-methylpropyl)-2H-thieno [3, 2-e]-1, 2, 3-thiadiazine-6- sulfonamide 1, 1-dioxide A-106 N NEZ > N/\/o'So oi 2- [2- (4-morpholinyl) ethyl]-2H-thieno [3, 2-e]-1, 2, 3-thiadiazine- 6-sulfonamide 1, 1-dioxide A-107 CHs N ! sO2NH2 I OUZO 4-methyl-2- (2omethylpropyl)-2H-thieno [3, 2-e]-1, 2, 3- thiadiazine-6-sulfonamide l, l-dioxide A-108 CH3 N ) )-SONHz I I S02NH2 OU nu 2- [2- (4-morpholmyl) ethyl]-4-methyl-2H-thieno [3, 2-e]-l, 2, 3- thiadiazine-6-sulfonamide 1, 1-dioxide

In another embodiment, the carbonic anhydrase inhibitor is selected from the class of thienothiazine sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula VIII shown below and possessing, by way of example and not limitation, the structures disclosed in Table 8. Furthermore, thienothiazine sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,510, 347, which is herein incorporated by reference in its entirety.

wherein: R3o is H or Cl 2 alkyl ; R31 is H; C16 alkyl unsubstituted or substituted optionally with OH, C1-4 alkoxy, NR34R35, OC (=O) R36 or C (=O) R36 ; R32 is H; C1-6 alkyl ; C2-4 alkyl substituted with OH, NR34R35, halogen, C1-4 alkoxy, C2-4 alkoxy, Cul-4 alkoxy, OC (=O) R36, S (=O) mR37, or C (=O) R36 ; C (=O) R36 ; R33 is H; C1-8 alkyl ; C1-8 alkyl substituted with OH, NR34R35, halogen, C14 alkoxy, C2-4 alkoxy, C14 alkoxy, OC (=O) R36, S (=O) mR37, or C (=O) R36; Cl7 alkenyl unsubstituted or substituted optionally with OH, NR34R35, or Cl4 alkoxy; C3-7 alkynyl unsubstituted or substituted optionally with OH, NR34R35, or Cl4 alkoxy; C13 alkyl substituted with R37 which can be unsubstituted or substituted optionally with C1-3 alkyl, Cri-3 haloalkyl, OH, (CH2) n NR34R35, halogen, C1-4 alkoxy, C14 haloalkoxy, OC (=O) R36, C (=O) R36, S (=O) m R38 or S02 NR34R35, wherein m is 0-2 and n is 0-2; R34 and R35 are H; Cl-8 alkyl ; C2-4 alkyl substituted optionally with OH, halogen, Ci-4 alkoxy or C (=O) R36; OH; Cri-4 alkoxy; C2-4 alkoxy substituted optionally with OH, halogen, Cri-4 alkoxy or C (=O) R36; or R34 and R35 can be joined to form a ring of 5 or 6 atoms selected from O, S, C or N which can be unsubstituted or substituted optionally on carbon with OH, (=O), halogen, C1 alkoxy, C (=O) R36, CI-6 alkyl, C1-6 alkyl substituted optionally with OH, halogen, C14 alkoxy, C (=O)) R36 or on nitrogen with C1-4 alkoxy, C (=O) R36, S (=O) m R3s, C1-6 alkyl or C2-6 alkyl substituted optionally with OH, halogen, Ci-4 alkoxy, C (=O) R36 or on sulfur by (=O) m, wherein m is 0-2; R36is C18 alkyl ; C1-4 alkyl substituted optionally with OH, NR34R35, halogen, C1-4 alkoxy or C (=O) R39 ; Cl4 alkoxy; C2-4 alkoxy substituted optionally with OH, NR34R35, halogen or Cl4 alkoxy; or NR34R35 ; R37 is a monocyclic ring system of 5 or 6 atoms composed of C, N, O or S, such as benzene, furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, isothiazole, thiazole, thiadiazole, pyridine pyrimidine, pyridazine, and

pyrazine, where R37 can be unsubstituted or substituted optionally with OH, (CH2) n NR34R3s, halogen, C1-4 alkoxy, C1-4 haloalkoxy, C (=O) R36, S (=O) m C1-4 alkyl or SO2 NR34R3s ; wherein m is 0-2 and n is 0-2; R38 is Cl 4 alkyl ; C2-4 alkyl substituted optionally with OH, NR34R35, C1-4 alkoxy or C (=O) R36 ; and R39 is Cl 4 alkyl ; C1 alkoxy ; amino, C1-3 alkylamino, of di-Cl-3 alkylamino. TABLEZ Compound No. Compound A-109 H H H3C,- N I NHz H"S S H OO 3, 4-dihydro-2H-thieno [3, 2-e]-1, 2, 3-thiadiazine-3-methyl-6- sulfonamide 1, 1-dixoide

In still another embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula VIIII shown below and possessing, by way of example and not limitation, the structures disclosed in Table 9. Furthermore, sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5, 538, 966, which is herein incorporated by reference in its entirety.

wherein G2, J and the two atoms of the thiophene ring to which they are attached form a six-membered ring chosen from:

wherein: Z4 is Z4a, Z4a is C1-8 alkyl ; C1-3 alkyl-C3-6 cycloalkyl ; CH2 C (=O) R46; CH2 C (=O) NR41R42 ; CH2CN ; C2-8 alkyl substituted with one or more of hydroxyl, C1 4 alkoxy, C2-4 alkoxy-C1-4 alkoxy, OC (=O) R4o, N (R41) C (=O) R4o, halogen, CN, NR41R42, SOnR43 or C (=O) R44, C1-4 alkyl substituted with an aromatic group chosen from phenyl or Q either of which can be unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, nitrile, NR41R42, SOnR43, C (=O) R44 or C14 alkyl which is substituted with hydroxy, NR4lR42, halogen, CO2R40 or C1-3 alkoxy ; C3-8 alkenyl unsubstituted or substituted with hydroxyl, C1-4 alkoxy or NR41R42 ; Cs-s alkynyl unsubstituted or substituted with hydroxyl, C1-4 alkoxy or NR41R41 ; and if Z4 is Z4b, Z4b is an aromatic group chosen from phenyl or Q either of which can be unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, hydroxy halogen, nitrile, NR41R42, SOnR43, C (=O) R44, or C1-4 alkyl which is substituted with hydroxy, NR41R42, halogen or C1-3 alkoxy; Y2 is hydrogen; C1-8 alkyl ; C1-6 alkyl substituted with one or more of hydroxyl, C1-4 alkoxy, C2-4 alkoxy-C1-4 alkoxy, OC (=O) R4o, N (R4l) C (=O) R4o, halogen, CN, NR4iR42, SOn R43, or C (=O) R44; C14 alkyl substituted with an aromatic group chosen from phenyl or Q either of which can be unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, hydroxy, halogen, nitrile, NR41R42, SOnR43, C (=O) R44 or Cl-4 alkyl which is substituted with hydroxy, NR4lR42, halogen, C02R40 or C1-3 alkoxy; C3-8 alkenyl unsubstituted or substituted with hydroxyl, C1-4 alkoxy or NR41R42 ; &num 3-8 alkynyl unsubstituted or substituted with hydroxyl, C1-4 alkoxy or NR41R42 ; R40 is C1-6 alkyl ; C1-6 alkyl substituted with hydroxyl, halogen, C1-4 alkoxy, NR41R42 or C (=O) R44 ; phenyl which can be unsubstituted or substituted with one or more of C1-4 alkyl, alkoxy, hydroxy or halogen; R41 and R42 are independently chosen from hydrogen; C1-4 alkyl ; CH2 CN; Cri-3 alkyl-C3-6 cycloalkyl ; C3-8 cycloalkyl ; C2-4 alkyl substituted with hydroxyl, halogen, CN,

C1-4 alkoxy or C (=O) R44; hydroxyl; C1-4 alkoxy; C24 alkoxy substituted with hydroxyl, NR4lR42, halogen or C14 alkoxy; C3-8 alkenyl unsubstituted or substituted with hydroxy, or C1 4 alkoxy; C3-8 alkynyl unsubstituted or substituted with hydroxyl, or C1-4 alkoxy; or further R41 and R42 together with the nitrogen atom to which they are attached can be incorporated into a saturated heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from O, S or N, such as pyrrolidine, oxazolidine, morpholine, thiomorpholine, thiomorpholine 1, 1-dioxide, piperazine, 2-oxa-5- azabicyclo [2.2. 1] heptane, 2-oxa-5-azabicyclo [3.2. 1] octane, thiazolidine, or thiazolidine 1,1-dioxide, which can be unsubstituted or substituted on carbon with hydroxyl, (=O), halogen, C14 alkoxy, C (=O) R44, C1-4 alkyl, C1-4 alkyl substituted with hydroxyl, halogen, C14 alkoxy, C (=O) R5, or on nitrogen with C1-4 alkoxy, C (=O) R44, SOn R43, Cl4 alkyl or C14 alkyl substituted with hydroxyl, halogen, Cul-4 alkoxy or C (=O) R44; R43 is C1-4 alkyl ; C2-4 alkyl substituted with hydroxyl, halogen, NR41R42 or C1-3 alkoxy; R44 is Cl-6 alkyl ; C1-6 alkyl substituted with hydroxyl, halogen, SOnR43, C1-4 alkoxy, NR41R42 or C (=O) R45 ; C1-4 alkyl substituted with an aromatic group chosen from phenyl or Q either of which can be unsubstituted or substituted with one or more of C14 alkyl, C14 alkoxy, hydroxy, halogen, nitrile, NR41R42, SOnR43 or C1-4 alkyl which is substituted with hydroxy, NR4lR42, halogen or C1-3 alkoxy; hydroxyl; C14 alkoxy ; C2-4 alkoxy substituted with hydroxyl, NR41R42, halogen or C1-4 alkoxy ; NR41R42 ; R45 is C1-4 alkyl ; C1-4 alkoxy; amino; C13 alkylamino ; (C1-3 alkyl) 2 amino; R46 is hydroxyl, C1 4 alkoxy, C1-4 alkoxy substituted with hydroxyl, NR41R42 or C1 4 alkoxy; n is 0, 1, or 2; and Q is a monocyclic five or six membered heterocyclic ring system wherein one or more of the heteroatoms nitrogen, oxygen and/or sulfur are incorporated into the ring, such as thiophene, furan, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, isothiazole, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, and pyrazine. TABLE 9 Compound No. Compound . K II,--S02NHNa H3COCH2CH2NX / 0--X--O 2- (2-methoxyethyl)-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide sodium salt A-111/\ ) --SOsNHNa H3COCH2CH2CH2Ns ~S OO oo 2- (2-methoxypropyl)-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide sodium salt A-112/\ \S02NHNa CH3CH20CH2CH2CH2-N S S 2- (3-ethoxypropyl)-2H-thieno [3, 2-el-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-113/\ NHz s H3CO"c 0 H3C0 2- (4-methoxyphenyl)-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-114 \ HO) y-soNHz HCI \ S02NH2 N s ouzo OJ 2- [2- (4-morpholinyl) ethyl]-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide hydrochloride TABLE 9 Compound No. Compound K A-115 HCI zon 3<SO2NH2 OJH CN /S Ouzo 2-methyl-3- (4-morpholinylmethyl)-2H-thieno [3, 2-e]-1, 2- thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-1 16 \SOZNH2 (CH30CHCH2) 2NN j S 0"0 HCI 2- [2- [bis (2-methoxyethyl) amino] ethyl]-2H-thieno [3, 2-e]-1, 2- thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-117 \S02NH2 CH3CH2CH2HN"-S S 0"0 HCI 2- [2- (propylamino) ethyl]-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide hydrochloride A-118/\ N S02NH2 nez )')-S (NH2 O N r"N s s ! ! cTo CH3 2 [2- [4-acetyl- (l-piperazinyl)]-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-119 0 N \ S02NH2 N S H3C0-CH2) s O 2- (3-methoxypropyl)-3- (4-morpholinyhnethyl)-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 9 Compound No. Compound A-120 (H3COCH2CH2) 2N H2CO N S02NH2 /\ N S H2CoL S 3- [ [bis (2-methoxyethyl) amino] methyl]-2- (4- methoxyphenylmethyl)-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-121 I NHz 0 01 ou 2- [4- (4-morpholinyl)-2-butenyl]-2H-thieno [3, 2-e]-1, 2-thiazine- 6-sulfonamide 1, 1-dioxide hydrochloride A-122/--\ HCI 0 N -N S02NH2 N S . \ O0 Mu0 2- (4-methoxyphenyhnethyl)-3- (4-morpholinylmethyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-123 (MeOCH2CH2) 2N 1 0 Met ouzo Mu0 3- [ [bis (2-methoxyethyl) amino] methyl]-2- (4-methoxyphenyl)- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-124/\ N/ H3 XSO2NH2 H CN S O O H3C 2- (1-methylethyl)-3- (4-morpholinyhnethyl)-2H-thieno [3, 2-e]- 1, 2-thiazine-6sulfonamide 1, 1-dioxide TABLE 9 TABLE 9 Compound No. Compound A-125 H HO S02NH2 H3C--N Hic 2- (1-methylethyl)-3- [ (2-propynylamino) methyl]-2H-thieno [3, 2- e]-1, 2-thiazine-6sulfonamide 1, 1-dioxide A-126 CH30 CH30 HCI N/ 0 HIC OO HgC 2- (l-methylethyl)-3- [ [ (2-methoxyethyl) (3- methoxypropyl) amino] methyl]-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide hydrochloride A-127 H NH/\ 0 oc3 Ouzo OCH3 OCH3 2- (3-methoxyphenyl)-3- [ (2-propynylamino) methyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-128 HCI N/\ H I \ S02NH2 Oh Ouzo OH OH 2-(3-hydroxyphenyl)-3-[(2-propynylamino) methyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 9 Compound No. Compound P A-129 Et-O/ N \ 0 Me N -c S02NH2 O Me/N me-- N- [ [6- (aminosulfonyl)-2-methyl-2H-thieno [3, 2-e]-1, 2-thiazine- 3-yllmethyl]-N-methyl-glycine ethyl ester S1, S'-dioxide A-130 HCI i Pr-O NHz II H I \ S02NH2 0 N S Mye O OO N-[[6-(aminosulfonyl)-2-methyl-2H-thieno [3, 2-e]-1, 2-thiazin- 3-yl] methyl]-glycine 2-methylethyl ester S', Sl-dioxide hydrochloride A-131 Me-O/ I I S02NH2 Mye N Mu Me S ouzo 3-[[(2-methoxyethyl) methylamino] methyl]-2-methyl-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-132 0 H C''O \ C \S02NH2 N, N r," 0 0 Oj HCI 3- [ (acetyloxy) methyl]-2- [2- (4-morpholinyl) ethyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-133 HCI EtO N >---S02NH2 O Meoi N--_s O MeOXJ zNs S J 0XS ; \\0 MeO Mezzo ethyl 4-[(2-methoxyethyl) [[6-(aminosulfonyl)-2-(2- methoxyethyl)-2H-thieno [3, 2-e]-1, 2-thiazin-2- yl] methyl] amino] butanoate Sl, Sl-dioxide hydrochloride TABLE 9 Compound No. Compound P A-134 HCI ''N ---S02NH2 N s jod EtOO 6- (aminosulfonyl)-3- (4-morpholinylmethyl)-2H-thieno [3, 2-e]- 1, 2-thiazine-2-butanoic acid 1, 1-dioxide ethyl ester A-135 / N I S02NH2 O Hou OUZO HO 2- (2-hydroxyethyl)-3- (4-morpholinylmethyl)-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-136 HCI ZON C S°2NH2 oui s Mye T MeO 2- [2- (acetyloxy) ethyl]-3- (4-morpholinylmethyl)-H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-137 3v SO2NH2 /I --S02NH2 0 N Ly ouzo 2-methyl-3- (4-morpholinylmethyl)-2H-thieno [2, 3-e]-1, 2- thiazine-6-sulfonamide 1, 1-dioxide

In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of thiophene sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula X shown below and possessing, by way of example and not limitation, the structures disclosed in Table 10. Furthermore, thiophene sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,646, 142, which is herein incorporated by reference in its entirety.

wherein: R47 is H; OH; C1-6 alkoxy; C1-6 alkyl unsubstituted or substituted optionally with OH, NR49Rso, OC (=O) Rsl or C (=O) R5i ; NR49Rso ; OC (=O) R5i ; C (=O) R5i ; C2-4 alkoxy substituted optionally with OH, NR49Rso, halogen, C1-4 alkoxy or C (=O) Rsl ; phenyl or R52 either of which can be unsubstituted or substituted optionally with OH, (CH2) nNR49R50, halogen, Cl alkoxy, C1-4 haloalkoxy, C (=O) Rsl, S (=O) m Rs3 or SO2 NR49R50 ; wherein m is 0-2 and n is 0-2; provided that when R47 is OH, alkoxy, NR49Rso or OC (=O) Rsl it is attached to the 4-position and when R47 is R52 and is attached to the 3 position, the R52 ring is attached by a carbon carbon single bond; R48 is C2-8 alkyl substituted with S (=O) R53 ; C4-7 alkenyl substituted with S (=O) mR53 wherein m is 0-2; R49 & Rso are H; C1-8 alkyl ; C2-4 alkyl substituted optionally with OH, halogen, C1-4 alkoxy or C (=O) Rsl ; C1-4 alkoxy; C2-4 alkoxy substituted optionally with OH, halogen, C1-4 alkoxy or C (=O) Rsl ; or R49 and Rso can be joined to form a ring of 5 or 6 atoms selected from O, S, C or N which can be unsubstituted or substituted optionally on carbon with OH, (=O), halogen, C1-4 alkoxy, C (=O) R51, C1-6 alkyl, C1-6 alkyl substituted optionally with OH, halogen, Cl-4 alkoxy, C (=O) Rsl or on nitrogen with C1-4 alkoxy, C (=O) R51, S (=O) mR53, Cl6 alkyl or C2-6 alkyl substituted optionally with OH, halogen, C1-4 alkoxy, C (=O) Rsl or on sulfur by (=O)m, wherein m is 0-2; R51 is Cl 8 alkyl ; C1-8 alkyl substituted optionally with OH, NR49R50, halogen, C1-4 alkoxy or C (=O) Rs4 ; C1-4 alkoxy; C2-4 alkoxy substituted optionally with OH, NR49R50, halogen or Ci-4 alkoxy; or NR49Rso ; Rs2 is a monocyclic ring system of 5 or 6 atoms composed of C, N, O or S, such as furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, isothiazole, thiazole, thiadiazole, pyridine pyrimidine, pyridazine, and pyrazine;

R53 is Cl alkyl ; C3-5 alkenyl, C2-4 alkyl substituted optionally with OH, NR49R50, Cl alkoxy or C (=O) Rsl ; phenyl or R52 either of which can be unsubstituted or substituted optionally with OH, (CH2) nNR49R5o, halogen, C1-4 alkoxy, C1-4 haloalkoxy, C (=O) R5i, S (=O) mC1-4 alkyl or SO2NR49R50; m is 0-2 and n is 0-2; and R54 is C1-4 alkyl ; C1-4 alkoxy; amino, C1-3 alkylamino, or di-Cl-3 alkylamino. TABLE 10 Compound No. Compound A-138 NHEt-C4H404 s S02NH2 OO OO (+)- (R)-4-ethylamino-3, 4-dihydro-2- (3-methylthiopropyl)-2H- thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide maleic acid A-139 OH I S02NH2 H3C SN S oo 3, 4-dihydro-4-hydroxy-2- (3-methylthiopropyl)-2H-thieno- [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-140 NHEt-HCI S02NH2 II,---S02NH2 00 OO (R)-4-ethylamino-3, 4-dihydro-2- [3- (l-methylethylthio) propyl]- 2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-141 3, 4-dihydro-4-propylamino-2- (3-methylthiopropyl)-2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-142 3, 4-dihydro-4- [ (2-methylpropyl) amino]-2- (3- methylthiopropyl)-2H-thieno- [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-143 3, 4-dihydro-4- [ (3-methylbutyl) amino]-2- (3-methylthiopropyl)- 2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide TABLE 10 Compound No. Compound A-144 3, 4-Dihydro-4-methylamino-2- (3-methylthiopropyl)-2H-thieno- [3, 2-e]-1, 2-thia zine-6-sulfonamide 1, 1-dioxide A-145 3, 4-Dihydro-4-hydroxy-2- (3-methylthiopropyl)-2H-thieno- [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-146 4-Ethylamino-3, 4-dihydro-2- (3-propylthiopropyl)-2H-thieno- [3, 2-e]-1, 2-thiaz ine-6-sulfonamide 1, 1-dioxide A-147 4-Ethylamino-3, 4-dihydro-2- (3-ethylthiopropyl)-2H-thieno- [3, 2-e]-1, 2-thiazi ne-6-sulfonamide 1, 1-dioxide A-148 4-Ethylamino-3, 4-dihydro-2- [3- (2-methoxyethylthio) propyl]- 2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-149 4-Ethylamino-3, 4-dihydro-2- [3- (3-methoxypropylthio) propyl] - 2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1,1-dioxide A-150 4-Ethylamino-3, 4-dihydro-2- [3- (2-methoxyethylthio) ethyl] -2H- thieno- [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-151 4-Ethylamino-3, 4-dihydro-2- [ (2-methylthio) ethyl] -2H-thieno- [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-152 3, 4-Dihydro-4-propylamino-2- [ (2-methylthio) ethyl) ]-2H- thieno- [3, 2-e]-1, 2-th iazine-6-sulfonamide 1,1-dioxide A-153 3, 4-Dihydro-4-[(2-methylpropyl) amino]-2-[(2- methylthio) ethyl]-2H-thieno- [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-154 4-Ethylamino-3, 4-dihydro-2- [ (4-methylthio) butyl]-2H-thieno- [3, 2-e]-1, 2-thia zine-6-sulfonamide 1, 1-dioxide A-155 3,4-Dihydro-4-propylamino-2- [ (4-methylthio) butyl] -2H-thieno- [3, 2-e]-1, 2-thi azine-6-sulfonamide 1, 1-dioxide A-156 3, 4-Dihydro-4- [ (2-methylpropyl) amino]-2- [ (4- methylthio) butyl]-2H-thieno- [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide

In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula XI shown below and possessing, by way of example and not limitation, the structures disclosed in Table 11. Furthermore, sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 5,932, 572 and 5,679, 670, both of which are herein incorporated by reference in their entirety. wherein: W and Y3 are as listed in Table A. TABLE A vCH2CH2 HN ! --S02NH2 /N (CH2) 20CH2CH3 XSso2NH2 0 (CH2) 2CH3 HN ! --SOsNHs /N (CH2) 20CH2CH3 S S oCH2CH3 HAN --SONH2 S02NH2 (CH2) 3oCH3 o,/X\o 0 HN/(CH2) 2CH3 HN S02NH2 /N (CH2) 3CH3 o/X\O 3 0 TABLE A CHCHg HN N /N (CH2) 20 (CH2) 2°CHg OO S / (CH2) zCHs _ HN 0 /N (CH2) 20 (CH2) 20CH/ad S /CH2CH3 HAN --S02NH2 N (CH2) 30 (CH2) 20CH3 o/X\O ouzo H/(CH2) 2CH3 HN f --S02NH2 /N (CH2) 30 (CH2) 20CH3--, N s S02NH2 Cr 0 oCH2CH3 HAN ! ! --S02NH2 S02NH2 (CH2) 2°CH3 OO S 0""0 un HN HN S02NH2 /(CH2) 2CH3 ß S02NH2 TABLE A HNoCH2CH3 HN S02NH2 CH3 Nj \ S ouzo HN CH2CH3 HN I r---S02NH2 /N (CH2) 4°CH O S 0 0 HN,- (CH2) 2CH3 HN --S02NH2 N (CH2) 40CH3 o/Amo 0 . HN S02NH2 N OCH3-Ph A, . oCH2CH3 HN ?--S02NH2 \-/ OH-Ph/NX S sCH2CH3 HN S02NH2 /N CH2CH (CH3) 2 00 S TABLE A , CH2CH3 HN nus I (CH2) S sCH2CH (CH3) 2 HN SO2NH N S (CH2) 3°H/OO o5--0 TABLE 11 Compound No. Compound A-157 NH-Et \S02NH2 H3CO- (CH2) 3N-S°2NH2 o-Amo (+)-4-Ethylamino-3, 4-dihydro-2- (3-methoxy) propyl-2H- thieno [3, 2-e]-1, 2-thia z ine-6-sulfonamide-1, 1-dioxide hydrochloride A-158 I NHz H (CH2) 3NX S o-Amo 3, 4-Dihydro-2- (3-methoxypropyl)-2H-thieno [3, 2-e]-1, 2- thiazine-6-sulfonamid e-1, 1-dioxide sodium salt TABLE 11 Compound No. Compound A-159 HN, CH2CH3 HCI HIC X S02NH2 w oxo 4-Ethylamino-3, 4-dihydro-2- (4-methylphenyl) methyl-2H- thieno [3, 2-e]-1, 2-thi a zine-6-sulfonamide 1, 1-dioxide hydrochloride A-160 3, 4-Dihydro-2- (3-phenylpropyl)-4-propylamino-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-161 3, 4-dihydro-2- (4-phenylbutyl)-4-propylamino-2H-thieno [3, 2- e]-1, 2-thiazine- 6-sulfonamide 1, 1-dioxide hydrochloride A-162 4-Ethylamino-3, 4-dihydro-2- (2-thienyl) methyl-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-163, CH2CH3 HCI I NHz nez HO Ho 4-Ethylamino-3, 4-dihydro-2- [4- (2-hydroxyethyl) phenyl]-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-164 2- (4-n-Butylphenyl)-3, 4-dihydro-4-propylamino-2H-thieno [3, 2- e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-165 3, 4-Dihydro-2-phenyl-4-propylamino-2H-thieno [3, 2-e]-1, 2- thiazine-6-sulfonamide 1, 1-dioxide tartrate A-166 (R)-4-Ethylamino-2- [4- (2-hydroxyethyl) phenyl]-3, 4-dihydro- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-167 (R)-4-Ethylamino-2- (4-methoxy-phenyl)-3, 4-dihydro-2H- thieno [3, 2-e]-1, 2-thi azine-6-sulfonamide 1, 1-dioxide hydrochloride A-168 (R)-4-Ethylamino-2- (4-hydroxy-phenyl)-3, 4-dihydro-2H- thieno [3, 2-e]-1, 2-thi azine-6-sulfonamide 1, 1-dioxide hydrochloride A-169 (R)-3, 4-Dihydro-2- (4-methoxy-phenyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-t hiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 11 Compound No. Compound A-170 (R)-3, 4-Dihydro-2- (4-hydroxy-phenyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-th iazine-6-sulfonamide 1, 1-dioxide hydrochloride A-171 (R)-4-Ethylamino-3, 4-dihydro-2- (3-methoxy-phenyl)-2H- thieno [3, 2-e]-1, 2-thi azine-6-sulfonamide 1, 1-dioxide hydrochloride A-172 (R)-4-Ethylaminio-3, 4-dihydro-2- (3-hydroxy-phenyl)-2H- thieno [3, 2-e]-1, 2-th iazine-6-sulfonamide 1, 1-dioxide hydrochloride A-173 (R)-3, 4-Dihydro-2- (3-methoxy-phenyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-th iazine-6-sulfonamide 1, 1-dioxide hydrochloride A-174 (R)-3, 4-Dihydro-2- (3-hydroxy-phenyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-th iazine-6-sulfonamide 1, 1-dioxide hydrochloride A-175/CH2CH2CH3 HCI HO f) -SOsNHs nez 00 S R- (+)-3, 4-Dihydro-2- (2-phenylethyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-176 (R)-4-Ethylamino-3, 4-dihydro-2- (4-methoxy-phenylmethyl)- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-177 (R)-4-Ethylamino-3, 4-dihydro-2- (4-hydroxy-phenylmethyl)- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-178 (R)-4-Ethylamino-3, 4-dihydro-2- (3-methoxy-phenylmethyl)- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-179 (R)-4-Ethylamino-3, 4-dihydro-2- (3-hydroxy-phenyhnethyl)- 2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 11 Compound No. Compound A-180 HN-Et HCI E H3CO- (CH2) 3-N S02NH2 OUZO 3, 4-Dihydro-2- (3-methoxypropyl)-3-methyl-2H-thieno>3, 2-e !- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-181 3, 4-Dihydro-2, 3-dimethyl-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide A-182 3, 4-Dihydro-2- (2-methoxyethyl)-3-methyl-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide A-183 CH2CH2CH2CH3 HO HN I \S02NH2 H3CO- (CH2) 4 N S OO R- (+)-3, 4-Dihydro-2- (4-methoxybutyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-184 ICI HUI HAN f (-S02NH2 H3CO- (CH2) 4 N S OO R- (+)-4-Ethylamino-3, 4-dihydro-2- (4-methoxybutyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-185 R- (+)-4-Ethylamino-3, 4-dihydro-2- (6-hydroxyhexyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-186 R- (+)-4-Allylamino-3, 4-dihydro-2- (2-methylpropyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-187 R- (+)-3, 4-Dihydro-2- (4-hydroxybutyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-188 R- (+)-3, 4-Dihydro-2- (2-methylpropyl)-4-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 11 Compound No. Compound A-189 R- (+)-4-Ethylamino-3, 4-dihydro-2- (2-methylpropyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-190 R- (+)-4-Cyclopropyhnethylamino-3, 4-dihydro-2- (2- methylpropyl)-2H-thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-191 R- (+)-4-Ethylamino-3, 4-dihydro-2- (3-methoxybutyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-192 R- (+)-3, 4-Dihydro-2- (3-methoxypropyl)-4- (2- methoxyethyl) amino-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide hydrochloride A-193 R- (+)-3, 4-Dihydro-2- (3-methoxybutyl)-4-n-propylamino-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-194 R- (+)-4-Ethylamino-3, 4-dihydro-2- (4-hydroxybutyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-195 (R)-3, 4-Dihydro-2- (3-hydroxypropyl)-4- (2- methylpropyl) amino-2H-thieno [3, 2-e]-1, 2-thiazine-6- sulfonamide 1, 1-dioxide hydrochloride A-196/CH2CH3 N \S02NH2 F- (CH2) 3NX ~S Q'0 0 4-Ethylamino-2- (3-fluoropropyl)-3, 4-dihydro-2H-thieno [3, 2-e]- 1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride A-197, CH2CH3 \SOZNH2 H3CO- (CH2) 3 N S OUZO R- (-)-4-Ethoxy-3, 4-dihydro-2- (3-methoxypropyl)-2H- thieno [3, 2-e]-1, 2-thiazine-6-sulfonamide 1, 1-dioxide hydrochloride TABLE 11 Compound No. Compound A-198 HCI HN<CH3 N ) f -S02NH2 I S02NH2 0 0R0 6-Ethyl-4-ethylamino-4, 5, 6, 7-tetrahydro-7-oxo-thieno [2, 3- b] pyridine-2-sulfonamide hydrochloride A-199 HCI H CH3 S02NH2 N S O 0 4-Ethylamino-4, 5, 6, 7-tetrahydro-7-oxo-6- (phenylmethyl)- thieno [2, 3-b] pyridine-2-sulfonamide hydrochloride A-200 N SO NH A-200 N'-,"S02NH2 s s s N- (2-Thienyl) methyl-2, 5-thiophenedisulfonamide A-201 N- (4-Trifluoromethylphenyl) methyl-2, 5- thiophenedisulfonamide A-202 N- (3, 5-Dichlorophenyl) methyl-2, 5-thiophenedisulfonamide A-203 N- (3, 4-Dichlorophenyl) methyl-2, 5-thiophenedisulfonamide A-204 N- (4-Methoxyphenyl) methyl-2, 5-thiophenedisulfonamide A-205 N- (4-Fluorophenyl) methyl-2, 5-thiophenedisulfonamide A-206 N- [ [4- (4-Morpholinyl methyl) phenyl] methyl]-2, 5-thiophene disulfonamide A-207 N- [ [3- (4-Morpholinylmethyl) phenyl] methyl]-2, 5- thiophenedisulfonamide hydrochloride A-208 ( \S/SOzNH2 0 N-(Phenylmethyl)-5-(aminosulfonyl)-thiophene-2-carboxamide In a further embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure

of Formula XII shown below and possessing, by way of example and not limitation, the structures disclosed in Table 12. Furthermore, sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 6,248, 735, 6,264, 935 and 6,316, 443, all of which are herein incorporated by reference in their entirety.

wherein: A4 is carbon or nitrogen; Z5iS N H R65 or oR65 ; R65 is C1-6 alkyl, either straight or branched chain; R66 is hydrogen, C1-3 alkyl, or Cl 4 alkoxy-Cz 4 alkyl ; and X3 is S (0) 2 or C (O) 2.

TABLE 12 Compound No. Compound A-209 (S, S)-(-)-5,6-Dihydro-4-ethylamino-6-methyl-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride A-210 (S, S)-(-)-5,6-Dihydro-4-ethylamino-6-(n-propyl)-4H- thieno [2,3-b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride A-211 (+-) -5, 6-dihydro-4-[(2-methylpropyl)amino]-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride A-212 (S, S)-(-)-5, 6-dihydro-4-ethylamino-6-methyl-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride A-213 (S, S)-(-)-5,6-dihydro-4-ethylamino-6-methyl-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride A-214 (S, S)- (-)-5, 6-dihydro-4-ethylamino-6-methyl-4H-thieno [2, 3- b] thiopyran-2-sulfonamide-7, 7-dioxide monohydrochloride In another embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formulas XIIIa, XIIIb, XIIIc, and XIIId shown below and possessing, by way of

example and not limitation, the structures disclosed in Table 13. Furthermore, sulfonamide carbonic anhydrase inhibitors useful in the practice of the present methods are described in U. S. Patent No. 6,313, 155, which is herein incorporated by reference in its entirety. wherein As together with the two carbon atoms denoted as a and ß is the group: wherein: X4 is S, SO, S02 or CH2; Y4 is S, O, or NR3 wherein R3 is hydrogen, C13 alkyl, or benzyl; n is 1 or 2 ; R', R68, R7'are independently selected from : (1) hydrogen, (2) OR71 wherein R71 is : (a) hydrogen, (b) Cl_5 alkyl, either unsubstituted or substituted with OH, or wherein R72 and R73 are independently hydrogen or C1-5 alkyl, or joined together form a heterocycle with the nitrogen to which they are attached such as piperidino, morpholino, or piperazino, (c) Ci-s alkanoyl, either unsubstituted or substituted with OH, NR72R73, NHCOR74 or COR74 wherein R74 is OH, NR72R73 or C1-5 alkoxy,

(d) CoR75, wherein R7s is NR72R73 or a 5 or 6-membered aromatic heterocycle such as pyridyl, imidazolyl, pyrazinyl, thiazolyl, thienyl, or oxazolyl, (3) NR73, (4) NHR76 wherein R76 is: (a) S02 NR72R73, (b) SO2R77, wherein R77 is C1-5 alkyl, or (c) ONR72R73, (5) C1-5 alkyl, either unsubstituted or substituted with (a) OR71, (b) CN, (c) NR72R73, or (d) COR74, (6) SO2R77, (7) SO2NR72R73, or (8)-halo, such as chloro, bromo or fluoro ; (9) R67 and R69, or R68 and R70 taken together represent a double bond; (10) R67 and R68, or R69 and R70 taken together represent (a) =O, or (b) =NoR78, wherein R78 is hydrogen or Cl 3 alkyl ; and one of the CH2 groups of (CH2) n can be substituted with COR74, CH2R74, or CH, COR74.

In yet another embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula XIIIb. wherein

wherein: X5 is S, SO2, or CH2; Ys is S, O, or NR85, wherein R85 is H, Cl 3 alkyl or benzyl, m is 0 or 1, is (1) hydrogen, (2) phenyl either unsubstituted or substituted with one or more of (a) hydroxy, (b) C1-3 alkoxy, (c) R83R84NC1-5 alkyl wherein R83 and R84 are independently selected from: (i) hydrogen and (ii) C1-5 alkyl, or taken together with the nitrogen to which they are attached form a heterocycle such as morpholine, piperidine, pyrrolidine, or piperazine, (3) OH, (4) =O ; or (5) NR83R84, WO is (1) hydrogen, (2) CN, (3) phenyl-Cl-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of (a) hydroxy,

(b) Cl-3 alkoxy, or (c) R83R84NC1-5 alkyl ; R81 is (1) hydrogen, (2) C1-5 alkyl, (3) phenyl-CI-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of : (a) hydroxy, (b) C1-3 alkoxy, or (c) R83R84NC1-3 alkyl ; (4) phenyl either unsubstituted or substituted with one or more of : (a) hydroxy, (b) C1-3 alkoxy, or (c) R83R84NC1-3 alkyl, or (d) halo, such as chloro or fluoro (5) aromatic heterocycle of 5 or 6 members such as furyl, pyridyl, or thienyl either unsubstituted or substituted with R83R84NC1-3 alkyl, (6) NRR, and (7) C2-5 alkyl substituted with NR83R84 ; R82 is (1) hydrogen, (2) Cl 3 alkyl, or (3) C1-3 alkylene, such as methylene; with the proviso that if R79 is other than phenyl or substituted phenyl, and leo is hydrogen, one of R81 and R82 is other than hydrogen.

In a further embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula XIIIc.

wherein: R86 is (1) H, (2) C1-4 alkyl, or (3) C2-4 alkyl substituted with (a) OH, (b) halogen, (c) Cl alkoxy, or (d) C (=O) R92, R87 is (1) H, (2) C1-8 alkyl, (3) C2-8 alkyl substituted with (a) OH, (b) NR, (c) halogen (d) C1-4 alkoxy, or (e) C (=O) R92, (4) C3-7 alkenyl unsubstituted or substituted with (a) OH, (b) NRV, or (c) C1-4 alkoxy, (5) C37 alkynyl, unsubstituted or substituted with (a) OH, (b) NR90R91, or (c) C1-4 alkoxy, (6) Cl 3 alkyl substituted with (a) phenyl, or (b) heteroaryl, unsubstituted or substituted with (i) OH, (ii) (CH2), NR\ (iii) halogen,

(iv) C1-4 alkoxy, (v) C1-4 haloalkoxy, (vi) C (=O) R92, (vii) S (=O) mR93, or (viii) SO2NR90R91; wherein m is 0-2 and n is 0-2, (7) C2-4 alkoxy substituted with (a) NR90R91, (b) halogen (c) C1-4 alkoxy, or (d) C (=O) R92; (8) phenyl, or (9) heteroaryl, unsubstituted or substituted with (a) OH, (b) (CH2)n NR90R91, (c) halogen, (d) C1-4 alkoxy, (e) C1-4 haloalkoxy, (f) C (=O) R92, (g) S (=O) mR93, or (h) SO2NR90R91; wherein m is 0-2 and n is 0-2, with the proviso that R86 and R87 cannot both be H, or R86 and R87 can form a saturated ring of 5 or 6 atoms selected from O, S, C, or N, said ring being unsubstituted or substituted on C with (1) OH, (2) NR90R91 (3) halogen, (4) Cl alkoxy, (5) C (=O) R92, (6) C1-6 alkyl, (7) C1-6 alkyl substituted with (a) OH,

(b) NR90R91, (c) halogen, (d) Clg alkoxy, (e) C (=O) R92 or substituted on N with (1) NR90R91, (2) C 1-4 alkoxy, (3) C (O) R (4) C1-6 alkyl, (5) Cl-6 alkyl substituted with (a) OH, (b) NR90R91, (c) halogen, (d) C1-4 alkoxy, or (e) C (=O) R92 ; R88 is (1) H, (2) halogen, (3) C1-4 alkyl, (4) C1-8 alkoxy, (5) C1-8 alkylthiol, (6) C2-8 alkoxy substituted with (a) OH, (b) NR90R91, (c) halogen, (d) Cl4 alkoxy, (e) C (=O) R92, (7) C1-4 alkyl substituted with R89, (8) R86 and R87 form a ring of 5 to 7 members, said ring being unsubstituted or substituted with R89 ; R89 is (1) OH, (2) C1-4 alkyl unsubstituted or substituted with

(a) OH (b) NRV, (c) halogen, (d) C1-4 alkoxy, or (e) C (=O) R92, (3) C1-4 alkoxy, (4) C2-4 alkoxy substituted with (a) OH, (b) NR90R91, (c) halogen, (d) C1-4 alkoxy or (e) C (=O) R ? 2, (5) NRV, (6) phenyl, or (7) heteroaryl, unsubstituted or substituted with (a) OH, (b) (CH2) nNR90R91, (c) halogen, (d) C1-4 alkoxy, (e) C1-4 haloalkoxy, (f) C (=O) R92, (g) S (=0) mR93, or (h) SO2NR9°R917 wherein m is 0-2 and n is 0-2; with the proviso that when R88 is in the 4 position and is H or halogen then R86 and R87 are not (1) H, (2) C1-6 alkoxy substituted with (a) OH, (b) C1-6 alkoxy, (c) C2-6 alkoxycarbonyl, or (3) joined to form a 5,6, or 7 member ring, saturated or unsaturated, comprised of atoms selected from C, O, S, N in which N, when saturated

is substituted with H or Cl 6 alkyl or in which C is substituted with C1-6 alkyl, C1-6 alkoxy or OH; and when R88 is in the 5 position and is H, Cl, Br or Cl 3 alkyl then R86 and W7 are not H or Cl 4 alkyl ; R90 and R91 are the same or different and are (1) H, (2) C1-4 alkyl, (3) C2-4 alkyl substituted with (a) OH, (b) halogen, (c) C1-4 alkoxy, or (d) C (=O) R92, (4) C1-4 alkoxy, (5) C2-4 alkoxy substituted with (a) OH, (b) halogen, (c) C1-4 alkoxy, or (d) C (=O) R92 (6) C3-7 alkenyl unsubstituted or substituted with (a) OH, (b) NR90R91, or (c) C1-4 alkoxy, (7) C3-7 alkynyl unsubstituted or substituted with (a) OH, (b) NR90R91, or (c) C1-4 alkoxy, (8) C12 alkyl C35 cycloalkyl or (9) R90 and R91 form a ring of 5 or 6 atoms selected from O, S, C, and N, said ring being unsubstituted or substituted on C with (a) OH, (b) (=O) (c) halogen, (d) C14 alkoxy,

(e) C (=O) R92, (f) C1-6 alkyl, (g) C1-6 alkyl substituted with (i) OH, (ii) halogen, (iii) C1-4 alkoxy, (iv) C (=O) R92 or on N with (a) C1-4 alkoxy, (b) C (=O) R92, (c) S (=O) mR937 (d) C1-6 alkyl, or (e) C2-6 alkyl substituted with (i) OH, (ii) halogen, (iii) C1-4 alkoxy, (iv) C (=O) R92 or on S with (=O) m wherein m is 0-2; R92 is (1) C1-8 alkyl, (2) Ci-s alkyl substituted with (a) OH, (b) NR90R91, (c) halogen, (d) C1-4 alkoxy, or (e) C (=O) R94, (3) C1-4 alkoxy, (4) C2-4 alkoxy substituted with (a) OH, (b) NR90R91, (c) halogen, or (d) C1-4 alkoxy, or

(5) NR90R91; <BR> <BR> <BR> R93 is<BR> <BR> <BR> <BR> <BR> <BR> <BR> (1) C14 alkyl, (2) C2-4 alkyl substituted with (a) OH, (b) NR90R91, (c) halogen, (d) C1-4 alkoxy, or (e) C (=O) R92 ; W4 is (1) C1-4 alkyl, (2) C1-4 alkoxy, (3) amino, (4) C1-3 alkylamino or (5) di-Cl-3 alkylamino, and G4 is C (=O) or SO2.

In still further embodiment, the carbonic anhydrase inhibitor is selected from the class of sulfonamide carbonic anhydrase inhibitors represented by the general structure of Formula XIIId. wherein R95 is (1) C1-18 alkyl, (2) C3-6 cycloalkyl, (3) C3-6 cycloalkyl C1-18 alkyl, (4) C1-18 alkyl C3-6 cycloalkyl, (5) haloalkyl, (6) aryl, unsubstituted or substituted with

(a) C1-10 alkyl, straight or branched, (b) halo selected from bromo, chloro and fluoro, or (c) alkoxy, selected from methoxy and ethoxy, (7) arylalkyl, where alkyl is C14 and aryl is unsubstituted or substituted with fluoro, chloro, bromo or C13 alkyl, (8) C2-18 hydroxyalkyl, (9) C2-18 aminoalkyl, (10) C2-6 alkenyl, (11) C26 alkynyl, or (12) aryl C2 6 alkenyl.

TABLE 13 Compound No. Compound A-215 5, 6-dihydro-4-ethylamino-6-methyl-4H-thieno [2,3-b] thiopyran- 2-sulfonamide-7, 7-dioxide A-216 5, 6-dihydro-4- (2-methylpropylamino)-6-methyl-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide A-217 5, 6-dihydro-6, 6-dimethyl-4-ethylamino-4H-thieno [2,3- b] thiopyran-2-sulfonamide-7, 7-dioxide A-218 5, 6-dihydro-5- (3-dimethylaminomethyl-4-hydroxybenzyl)-4H- thieno [2, 3-b] thiopyran-2-sulfonamide-7, 7-dioxide A-219 5, 6-dihydro-6- (3-dimethylaminomethyl-4-hydroxyphenyl)-4H- thieno [2,3-b] thiopyran-2-sulfonamide-7, 7-dioxide A-220 (+)-3, 4-dihydro-4-ethylamino-2-methyl-4H-thieno [3,2-e]-1, 2- thiazine-6-sulfonamide-1, 1-dioxide A-221 3, 4-dihydro-4-methoxy-2-methyl-4H-thieno [3,2-e]-1, 2- thiazine-6-sulfonamide-1, 1-dioxide A-222 3, 4-dihydro-2-methyl-4 (2-methyl) propylamino-4H-thieno [3,2- e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide A-223 3,4-dihydro-4-methoxy-2- [2- (4-morpholino) ethyl] -4H- thieno [3, 2-e]-1, 2-thiazi ne-6-sulfonamide-1, 1-dioxide A-224 3,4-dihydro-4-ethylamino-2-allyl-4H-thieno [3, 2-e]-1, 2-thiazine- 6-sulfonamid e-1, 1-dioxide A-225 3, 4-dihydro-4-ethylamino-2-n-propyl-4H-thieno [3, 2-e]-1, 2- thiazine-6-sulfona mide-1, 1-dioxide A-226 3, 4-dihydro-4-ethylamino-2- (2-methoxyethyl)-4H-thieno [3,2- e]-1, 2-thiazine-6-sulfonamide-1, 1-dioxide A-226 3, 4-dihydro-4-hydroxy-2- [2- (4-morpholino) ethyl] -4H- thieno [3,2-e]-1, 2-thiazi ne-6-sulfonamide-1, 1-dioxide The carbonic anhydrase inhibitor employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. Generally speaking, suitable carbonic

anhydrase inhibitors that are in tautomeric, geometric or stereoisomeric forms are those compounds that inhibit carbonic anhydrase activity by about 25%, more typically by about 50%, and even more typically, by about 75% or more when present at a concentration of 100 jj, M or less. The present invention contemplates all such compounds, including cis-and trans-geometric isomers, E-and Z-geometric isomers, R- and S-enantiomers, diastereomers, d-isomers, 1-isomers, the racemic mixtures thereof and other mixtures thereof. Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention. The terms "cis"and"trans", as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond ("cis") or on opposite sides of the double bond ("trans"). Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or"E"and"Z"geometric forms. Furthermore, some of the compounds described contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

Generally speaking, the pharmacokinetics of the particular agent to be administered will dictate the most preferred method of administration and dosing regiment. The carbonic anhydrase inhibitor can be administered as a pharmaceutical composition with or without a carrier. The terms"pharmaceutically acceptable carrier" or a"carrier"refer to any generally acceptable excipient or drug delivery composition that is relatively inert and non-toxic. Exemplary carriers include sterile water, salt solutions (such as Ringer's solution), alcohols, gelatin, talc, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, calcium carbonate, carbohydrates (such as lactose, sucrose, dextrose, mannose, albumin, starch, cellulose, silica gel, polyethylene glycol (PEG), dried skim milk, rice flour, magnesium stearate, and the like.

Suitable formulations and additional carriers are described in Remington's Pharmaceutical Sciences, (17. sup. th Ed. , Mack Pub. Co. , Easton, Pa. ). Such preparations can be sterilized and, if desired, mixed with auxiliary agents, e. g. , lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, preservatives and/or aromatic substances and the like which do not deleteriously react with the active compounds. Typical preservatives can include, potassium sorbate, sodium metabisulfite, methyl paraben, propyl paraben, thimerosal,

etc. The compositions can also be combined where desired with other active substances, e. g. , enzyme inhibitors, to reduce metabolic degradation.

Moreover, the carbonic anhydrase inhibitor can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The method of administration can dictate how the composition will be formulated. For example, the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, or magnesium carbonate.

In another embodiment, the carbonic anhydrase inhibitor can be administered intravenously, parenterally, intramuscular, subcutaneously, orally, nasally, topically, by inhalation, by implant, by injection, or by suppository. For enteral or mucosal application (including via oral and nasal mucosa), particularly suitable are tablets, liquids, drops, suppositories or capsules. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Liposomes, microspheres, and microcapsules are available and can be used. Pulmonary administration can be accomplished, for example, using any of various delivery devices known in the art such as an inhaler. See. e. g. S. P.

Newman (1984) in Aerosols and the Lung, Clarke and Davis (eds. ), Butterworths, London, England, pp. 197-224; PCT Publication No. WO 92/16192; PCT Publication No. WO 91/08760. For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. In particular, carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-polyoxypropylene block polymers, and the like.

The actual effective amounts of compound or drug can and will vary according to the specific composition being utilized, the mode of administration and the age, weight and condition of the subject. Dosages for a particular individual subject can be determined by one of ordinary skill in the art using conventional considerations. But in general, the amount of carbonic anhydrase inhibitor will be between about 0.5 to about 2000 milligrams per day and more typically, between about 100 to about 1000 milligrams per day. The daily dose can be administered in one to four doses per day.

By way of example, in one embodiment when the carbonic anhydrase inhibitor is acetazolamide administered orally, the daily dosage is typically from about 250 to about 1000 milligrams per day administered in one to four doses per day. In another embodiment, when the carbonic anhydrase inhibitor is acetazolamide administered as an injection, the daily dosage is typically from about 100 to about 500 milligrams per day, but it is administered in one or two doses per day.

By way of further example, in another embodiment when the carbonic anhydrase inhibitor is dichlorphenamide administered orally, the daily dosage is typically from about 25 to about 200 milligrams administered in one to three doses per day.

By way of yet further example, in another embodiment when the carbonic anhydrase inhibitor is methazolamide administered orally, the daily dosage is typically from about 75 to about 300 milligrams administered in one to three doses per day.

In general, the timing of the administration of the cyclooxygenase-2 selective inhibitor in relation to the administration of the carbonic anhydrase inhibitor may also vary from subject to subject. In one embodiment, the cyclooxygenase-2 selective inhibitor and carbonic anhydrase inhibitor may be administered substantially simultaneously, meaning that both agents may be administered to the subject at approximately the same time. For example, the cyclooxygenase-2 selective is administered during a continuous period beginning on the same day as the beginning of the carbonic anhydrase inhibitor and extending to a period after the end of the carbonic anhydrase inhibitor. Alternatively, the cyclooxygenase-2 selective inhibitor and carbonic anhydrase inhibitor may be administered sequentially, meaning that they are administered at separate times during separate treatments. In one embodiment, for example, the cyclooxygenase-2 selective inhibitor is administered during a continuous period beginning prior to administration of the carbonic anhydrase inhibitor and ending after administration of the carbonic anhydrase inhibitor. Of course, it is also possible that the cyclooxygenase-2 selective inhibitor may be administered either more or less frequently than the carbonic anhydrase inhibitor. Moreover, it will be apparent to those skilled in the art that it is possible, and perhaps desirable, to combine various times and methods of administration in the practice of the present invention.

Ifidication to be Treated Generally speaking, the composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor and a therapeutically effective amount of a carbonic anhydrase inhibitor may be employed to treat any type of neoplasia or neoplasia related disorder in a subject irrespective of its stage of progression.

In some aspects, the composition may be administered to either prevent the onset of clinically evident neoplasia altogether or to prevent the onset of a preclinically evident stage of neoplasia in subjects at risk for developing neoplasia. In other aspects, the composition may be administered to prevent the initiation of malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. In still other aspects, the composition may be administered to inhibit neoplasia growth, spreading or metastasis, as well as partial or total destruction of the neoplasia cells.

The composition may be effectively employed to treat a number of different types of neoplasia. In one embodiment, the neoplasia is epithelial cell-derived neoplasia (epithelial carcinoma). By way of example, epithelial cell-derived neoplasia includes basal cell carcinoma, squamous cell carcinoma or adenocarcinoma. In another embodiment, the neoplasia is a gastrointestinal cancer. Gastrointestinal cancers include lip cancer, mouth cancer, esophogeal cancer, small bowel cancer, stomach cancer and colon cancer. In still another embodiment, the neoplasia is liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, brain cancer and renal cell carcinoma. The composition can also be used to treat fibrosis that often occurs with radiation therapy. In yet another embodiment, the composition can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP).

The cyclooxygenase-2 selective inhibitor and carbonic anhydrase inhibitor may also be administered with any other drug or agent known in the art to have utility for treating or preventing neoplasia disorders or related diseases. In one embodiment, the antineoplastic agent is an antimetabolite including folate antagonists (e. g. methotrexate), pyrimidine antagonists (e. g. cytarabine, floxuridine, fludarabine, fluorouracil, and gemcitabine), purine antagonists (e. g. cladribine, mercaptopurine, thioguanine), and adenosine deaminase inhibitors (e. g. pentostatin). In an alternative embodiment, the antineoplastic agent is an alkylating agent such as chlorambucil, cyclophosphamide,

busulfan, ifosfamide, melphalan, and thiotepa. In yet another embodiment, the antineoplastic agent is an akylator agent such as cisplatin, carboplatin, procarbazine, dacarbazine, and altretamine. In still another embodiment, the antineoplastic agent is an anti-tumor antibiotic such as bleomycin, dactinomycin, and mitomycin. In yet a further embodiment, the antineoplastic agent is an immunological agent such as interferon. In another embodiment, the antineoplastic agent is a plant alkaloid including vinca alkaloids (e. g. vinblastine vincristine and vinorelbine), epipodophyllotoxins (e. g. etoposide and teniposide), taxanes (e. g. docetaxel and paclitaxel), and camptothecins (e. g. topotecan and irinotecan). Of course those skilled in the art will appreciate that the particular antineoplastic agents to be administered with the composition of the invention will vary considerably depending on the type of neoplasia disorder being treated and its stage of progression.

EXAMPLES Example 1-Determining Whether A Composition Reduces Tumor Cell Growth The ability of a composition of the invention to reduce the growth of tumor cells can readily be determined. As used in the examples, the term"composition"shall include any composition comprising a cyclooxygenase-2 selective inhibitor and carbonic anhydrase inhibitor detailed herein. By way of example, the cyclooxygenase-2 selective inhibitor utilized for testing the composition may be celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, or deracoxib. The carbonic anhydrase inhibitor may include acetazolamide, methazolamide, dorzolamide, or brinzolamide. Moreover, various cell lines can be used to determine whether the composition reduces growth of tumor cells.

For example, these cell lines include: SW-480 (colonic adenocarcinoma) ; HT-29 (colonic adenocarcinoma), A-427 (lung adenocarcinoma carcinoma); MCF-7 (breast adenocarcinoma); UACC-375 (melanoma line); and DU-145 (prostrate carcinoma).

Cytotoxicity data obtained using these cell lines are indicative of an inhibitory effect on neoplastic lesions. These cell lines are well characterized, and are used by the United States National Cancer Institute in their screening program for new anti-cancer drugs.

By way of illustration, a composition's ability to inhibit tumor cell growth can be measured using the HT-29 human colon carcinoma cell line obtained from ATCC and a SRB assay. HT-29 cells have previously been characterized as a relevant colon tumor cell culture model and may be (Fogh, J. , and Trempe, G. In : Human Tumor Cells in

Vitro, J. Fogh (eds. ), Plenum Press, New York, pp. 115-159,1975). In this assay, HT-29 cells are maintained in RPMI media supplemented with 5% fetal bovine calf serum (Gemini Bioproducts, Inc. , Carlsbad, Calif. ) and 2 mm glutamine, and 1% antibiotic- antimycotic in a humidified atmosphere of 95% air and 5% C02 at 37° C. Briefly, HT-29 cells are plated at a density of 500 cells/well in 96 well microtiter plates and incubated for 24 hours at 37 °C. prior to the addition of compound. Each determination of cell number involves six replicates. After six days in culture, the cells are fixed by the addition of cold trichloroacetic acid to a final concentration of 10% and protein levels are measured using the sulforhodamine B (SRB) colorimetric protein stain assay as previously described by Skehan, P. , Storeng, R. , Scudiero, D. , Monks, A. , McMahon, J., Vistica, D. , Warren, J. T. , Bokesch, H. , Kenney, S. , and Boyd, M. R. ,"New Colorimetric Assay For Anticancer-Drug Screening, "J. Natl. Cancer Inst. 82 : 1107-1112,1990, which is incorporated herein by reference.

In addition to the SRB assay described above, a number of other methods are available to measure growth inhibition and could be substituted for the SRB assay. These methods include counting viable cells following trypan blue staining, labeling cells capable of DNA synthesis with BrdU or radiolabeled thymidine, neutral red staining of viable cells, or MTT staining of viable cells.

Significant tumor cell growth inhibition greater than about 50% at a therapeutically effective dose is indicative that the composition is useful for treating neoplastic lesions.

Example 2-Mammary Gland Organ Culture Model Tests Compositions can also be tested for antineoplastic activity by their ability to inhibit the incidence of pre-neoplastic lesions in a mammary gland organ culture system.

This mouse mammary gland organ culture technique has been successfully used by other investigators to study the effects of known antineoplastic agents such as certain NSAIDs, retinoids, tamoxifen, selenium, and certain natural products.

For example, female BALB/c mice can be treated with a combination of estradiol and progesterone daily, in order to prime the glands to be responsive to hormones in vitro. The animals are sacrificed, and thoracic mammary glands are excised aseptically and incubated for ten days in growth media supplemented with insulin, prolactin, hydrocortisone, and aldosterone. DMBA (7,12 dimethylbenz (a) anthracene) is added to

medium to induce the formation of premalignant lesions. Fully developed glands are then deprived of prolactin, hydrocortisone, and aldosterone, resulting in the regression of the glands but not the pre-malignant lesions.

The test composition is dissolved in DMSO and added to the culture media for the duration of the culture period. At the end of the culture period, the glands are fixed in 10% formalin, stained with alum carmine, and mounted on glass slides. The incidence of forming mammary lesions is the ratio of the glands with mammary lesions to glands without lesions. The incidence of mammary lesions in test composition treated glands is compared with that of the untreated glands.

The extent of the area occupied by the mammary lesions can be quantitated by projecting an image of the gland onto a digitation pad. The area covered by the gland is traced on the pad and considered as 100% of the area. The space covered by each of the non-regressed structures is also outlined on the digitization pad and quantitated by the computer.